The 81st Annual Scientific Meeting of the Japanese Circulation Society

Program

Final Program(PDF)

1. Mikamo Lecture(Sponsored by Japan Heart Foundation)

March 18 (Sat) 11:55-12:40

Room1(Ishikawa Ongakudo, 2F, Concert Hall)

Speaker: Christine E. Seidman(Harvard Medical School, USA)
Chairperson: Masatsugu Hori(Osaka Medical Center for Cancer and Cardiovascular Diseases)

2. Mashimo Memorial Lecture

Vascular Endothelial Growth Factor and its Receptor System:A Critical Regulator for Physiological and Pathological Angiogenesis

March 18 (Sat) 11:10-11:55

Room1(Ishikawa Ongakudo, 2F, Concert Hall)

Speaker: Masabumi Shibuya(Jobu University)
Chairperson: Yoshio Yazaki(International University of Health and Welfare)

3. Congress Chairperson's Lecture

March 18 (Sat) 15:15-16:00

Room1(Ishikawa Ongakudo, 2F, Concert Hall)

Speaker: Masakazu Yamagishi(Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine)
Chairperson: Tsuneaki Sugimoto(Tokyo University)

Special Lectures

(1)
Emerging Advances in Cardiac Ultrasound
March 17 (Fri) 11:30-12:15
Room2(Ishikawa Ongakudo, 2F, Hogaku Hall)
Speaker: Anthony N. DeMaria(University of California, USA)
Chairperson: Masakazu Yamagishi(Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine)
(2)
The Changing Genetic Landscape of Dilated Cardiomyopathy
March 17 (Fri) 12:15-13:00
Room2(Ishikawa Ongakudo, 2F, Hogaku Hall)
Speaker: Diane Fatkin(Victor Chang Cardiac Research Institute, Australia)
Chairperson: Tohru Masuyama(Department of Cardiovascular Medicine, Hyogo College of Medicine)
(3)
Transcatheter Interventions in Adult Congenital Heart Disease
March 17 (Fri) 14:20-15:05
Room2(Ishikawa Ongakudo, 2F, Hogaku Hall)
Speaker: Jamil Aboulhosn(Ronald Reagan UCLA Medical Center, USA)
Chairperson: Fukiko Ichida(Department of Pediatrics Cardiology, University of Toyama, Toyama)
(4)
The Implication of PCSK9 in Cardiometabolic Disorders
March 17 (Fri) 15:05-15:50
Room2(Ishikawa Ongakudo, 2F, Hogaku Hall)
Speaker: Nabil G. Seidah(Clinical Research Institute of Montreal, Canada)
Chairperson: Toyoaki Murohara(Department of Cardiology, Nagoya University Graduate School of Medicine)
(5)
The Development and Current Status of BVS
March 17 (Fri) 17:00-17:45
Room2(Ishikawa Ongakudo, 2F, Hogaku Hall)
Speaker: Krishnankutty Sudhir(Abbott Vascular, USA)
Chairperson: Takeshi Kimura(Kyoto University Hospital Cardiovascular Medicine)
(6)
The Changing Face of the Pathogenesis of the Acute Coronary Syndromes (ACS)
March 17 (Fri) 17:45-18:30
Room2(Ishikawa Ongakudo, 2F, Hogaku Hall)
Speaker: Peter Libby(Harvard Medical School, USA)
Chairperson: Katsunori Ikewaki(Neurology, Anti-aging, and Vascular Medicine, National Defense Medical College)
(7)
Improving Cardiovascular Outcomes by Integrating Research and Reality
March 18 (Sat) 8:30-9:15
Room2(Ishikawa Ongakudo, 2F, Hogaku Hall)
Speaker: Lars Wallentin(Uppsala Clinical Research Center, Sweden)
Chairperson: Hiroshi Ito(Department of Cardiovascular and Respiratory Medicine, Akita University Graduate School of Medicine)
(8)
TAVI: the Revolution, Has Started
March 18 (Sat) 9:15-10:00
Room2(Ishikawa Ongakudo, 2F, Hogaku Hall)
Speaker: Thierry Lefevre(Institut Hospitalier Jacques Carier, France)
Chairperson: Yasuki Kihara(Department of Cardiovascular Medicine, Hiroshima University and Health Sciences, Hiroshima University)
(9)
PCSK9 Inhibitors; Does Reducing LDL Cholesterol to Low and Very Low Levels Have Additional Benefit on CVD Events or Safety Concerns?
March 18 (Sat) 11:10-11:55
Room2(Ishikawa Ongakudo, 2F, Hogaku Hall)
Speaker: Evan A. Stein(Metabolic and Atherosclerosis Research Center, USA)
Chairperson: Keijiro Saku(Department of Cardiology, Fukuoka University School of Medicine)
(10)
Genetics of Coronary Artery Disease: Discovery, Biology, and Clinical Translation
March 18 (Sat) 11:55-12:40
Room2(Ishikawa Ongakudo, 2F, Hogaku Hall)
Speaker: Sekar Kathiresan(Massachusetts General Hospital,USA)
Chairperson: Ryozo Nagai(Jichi Medical University)
(11)
2015 ESC Non-ST-elevation Acute Coronary Syndromes Guideline and Beyond
March 18 (Sat) 14:30-15:15
Room2(Ishikawa Ongakudo, 2F, Hogaku Hall)
Speaker: Marco Roffi(Geneva University Hospital, Switzerland)
Chairperson: Yukio Ozaki(Department of Cardiology, Fujita Health University School of Medicine)
(12)
Mitochondria, Inflammation and Heart Failure
March 18 (Sat) 17:20-18:05
Room2(Ishikawa Ongakudo, 2F, Hogaku Hall)
Speaker: Kinya Otsu(King's College London, UK)
Chairperson: Hiroshi Ito(Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine)
(13)
Cardiogenetics; Are We on the Right Track?
March 18 (Sat) 18:05-18:50
Room2(Ishikawa Ongakudo, 2F, Hogaku Hall)
Speaker: Arthur A. M. Wilde(University of Amsterdam, The Netherlands)
Chairperson: Kazutaka Aonuma(Department of Cardiology, University of Tsukuba)
(14)
Cardiac iPSCs: from Personalized Medicine to Clinical Trial in a Dish
March 19 (Sun) 8:30-9:15
Room2(Ishikawa Ongakudo, 2F, Hogaku Hall)
Speaker: Joseph C. Wu(Stanford University School of Medicine, USA)
Chairperson: Keiichi Fukuda(Department of Cardiology, Keio University School of Medicine)
(15)
Complexity of the Aorta: the Basis for Aneurysmal Locations
March 19 (Sun) 9:15-10:00
Room2(Ishikawa Ongakudo, 2F, Hogaku Hall)
Speaker: Alan Daugherty(University of Kentucky, USA)
Chairperson: Hiroaki Shimokawa(Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine)

Special Sessions

(1)

March 17 (Fri) 11:10-12:40

Room1(Ishikawa Ongakudo, 2F, Concert Hall)

Chairperson: Mitsuaki Isobe(Department of Cardiovascular Medicine, Tokyo Medical and Dental University)
Shinji Nagahiro(Department of Neurosurgery, Tokushima University Graduate School)
Speaker: Ken Okumura(Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center)
Takashi Ashikaga(Department of Cardiology and Regional Medicine, Tokyo Medical and Dental University)
Hiroyuki Takao(Department of Innovation of Medical Information Technology, The Jikei University)
Michiyasu Suzuki(Department of Neurosurgery, Yamaguchi University School of Medicine)
(2)

March 17 (Fri) 11:30-13:00

Room9(Kanazawa Miyako Hotel, B2F, Seminar Hall)

Chairperson: Uichi Ikeda(Nagano Municipal Hospital)
Fukiko Ichida(Department of Pediatric Cardiology, University of Toyama)
Speaker: Kunio Ohta(Department of Pediatrics, Kanazawa University)
Jun Koyama(Division of Cardiovascular Medicine, Shinshu University School of Medicine)
Keiichi Hirono(Department of Pediatrics, Graduate School of Medicine, University of Toyama)
Taishiro Chikamori(Department of Cardiology, Tokyo Medical University)
Nobukazu Ishizaka(Department of Cardiology, Osaka Medical College)
Toru Kubo(Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University)
(3)

March 17 (Fri) 11:30-13:00

Room11(Kanazawa Miyako Hotel, 7F, Hoh-Oh)

Chairperson: Isao Kubota(Internal Medicine Ⅰ, Yamagata University)
Masao Yoshizumi(Department of Cardiovascular Physiology and Medicine, Hiroshima University)
Speaker: Junichi Sadoshima(Rutgers New Jersey Medical School, USA)
Takahisa Nakamura(Cincinnati Children's Hospital, USA)
Osamu Fujimura(University of California, USA)
Takahiro Higuchi(University of Würzburg, Germany)
Kinya Otsu(King's College London, UK)
(4)Protection of Youngsters from Cardiovascular Disease: a Recommendation for the Kanazawa Declaration
(※Partly in English)

March 17 (Fri) 14:20-15:50

Room1(Ishikawa Ongakudo, 2F, Concert Hall)

Chairperson: Hiroyasu Iso(Public Health, Osaka University Graduate School of Medicine)
Issei Komuro(Department of Cardiovascular Medicine, The University of Tokyo)
Speaker: Issei Komuro(Department of Cardiovascular Medicine, The University of Tokyo)
Latha Palaniappan(Stanford University School of Medicine, USA)
Hiroyasu Iso(Public Health, Osaka University Graduate School of Medicine)
Kazumasa Yamagishi(Department of Public Health Medicine, Facutly of Medicine, University of Tsukuba)
Yusuke Ohya(Department of Cardiovascular Medicine, Nephrology and Neurology, University of the Ryukyus)
Koichi Node(Department of Cardiovascular Medicine, Saga University)
Atsushi Nohara(Medical Education Research Center, Kanazawa University Graduate School of Medical Sciences)
(5-1)Basic Researches of Cardiovascular Medicine from Japan for Next Generation

March 17 (Fri) 14:20-14:55

Room3(ANA Crowne Plaza Kanazawa, 3F, Ohtori)

Chairperson: Akira Kitabatake(Hokkaido University Graduate School of Medicine)
Speaker: Kinya Otsu(King's College London, UK)
(5-2)

March 17 (Fri) 14:55-15:30

Room3(ANA Crowne Plaza Kanazawa, 3F, Ohtori)

Chairperson: Shigetake Sasayama(Uji Hospital)
Speaker: Shigekazu Nagata(Osaka University Immunology Frontier Research Center)
(5-3)

March 17 (Fri) 15:30-16:05

Room3(ANA Crowne Plaza Kanazawa, 3F, Ohtori)

Chairperson: Masunori Matsuzaki(Yamaguchi University)
Speaker: Hiroshi Mabuchi(Kanazawa University)
(6)Science Policy for Cardiovascular Medical Research and Development in Japan

March 17 (Fri) 17:00-18:30

Room9(Kanazawa Miyako Hotel, B2F, Seminar Hall)

Chairperson: Jun Yamashita(Center for iPS Cell Research and Application (CiRA), Kyoto University)
Shinsuke Yuasa(Department of Cardiology, Keio University School of Medicine)
Speaker: Shinsuke Yuasa(Department of Cardiology, Keio University School of Medicine)
Ichiro Hisatome(Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Science)
Atsuhiko Naito(Department of Pharmacology, Toho University)
Chiaki Nakanishi(Division of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine)
Jun Yamashita(Center for iPS Cell Research and Application(CiRA), Kyoto University)
(7)Excellent Case Presentation by Young Careers in English

March 17 (Fri) 17:00-18:30

Room14(Hotel Kanazawa, 2F, Diamond C)

Chairperson: Osamu Fujimura(University of California, USA)
Mark H. Swartz(Clinical Competence Center of New York, USA)
(8)

March 18 (Sat) 8:30-10:00

Room11(Kanazawa Miyako Hotel, 7F, Hoh-Oh)

Chairperson: Yoshiyu Takeda(Innovative Clinical Research Center, Kanazawa University)
Speaker: Kenichi Yoshimura(Kanazawa University Hospital)
Yoshitaka Murakami(Department of Medical Statistics, Toho University)
(9)

March 18 (Sat) 11:10-12:40

Room14(Hotel Kanazawa, 2F, Diamond C)

Chairperson: Yasushi Sakata(Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine)
Hitoshi Yokoyama(Department of Cardiovascular Surgery, Fukushima Medical College)
Speaker: Kunio Miyatake(Yoshida-onoharahigashi Clinic)
Takuro Misaki(Toyama University)
Soichiro Kitamura(National Cerebral and Cardiovascular Center)
Keiji Igaki(Kyoto Medical Planning Co., Ltd.)
(10)

March 18 (Sat) 14:30-16:00

Room5(Hotel Nikko Kanazawa, 3F, Kujaku BC)

Chairperson: Yasuki Kihara(Department of Cardiovascular Medicine, Hiroshima University)
Tsutomu Yoshikawa(Sakakibara Heart Institute)
Speaker: Shun Kohsaka(Keio University School of Medicine)
Fumio Terasaki(Medical Education Center, Department of Cardiology, Osaka Medical College)
Yoshitaka Iwanaga(Faculty of Medicine, Kindai University)
Takeshi Shirayama(Kyoto Prefectural University of Medicine)
Hidehiko Hara(Division of Cardiovascular Medicine, Toho University Ohashi Medical Center)
Masaomi Chinushi(School of Health Sciences, Niigata University)
(11)How to Realize the International Authentication of Medical Education of Cardiovascular Medicine

March 19 (Sun) 14:00-15:30

Room11(Kanazawa Miyako Hotel, 7F, Hoh-Oh)

Chairperson: Andrew Schneider(Program Management Office for New Paradigms, Establishing Centers for Fostering Medical Researchers of the Future Kanazawa University School of Medicine)
Kiyoshi Kitamura(International University of Health and Welfare)
Speaker: Osamu Fujimura(University of California, USA)
Kiyoshi Kitamura(International University of Health and Welfare)
Masahiro Ito(Comprehensive Medical Education Center, Niigata University School of Medicine)
Eiji Gotoh(Yokohama City University / Yokohama Hodogaya Central Hospital)
(12)

March 19 (Sun) 16:40-18:10

Room1(Ishikawa Ongakudo, 2F, Concert Hall)

Chairperson: Hiroaki Shimokawa(Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine)
Kazuomi Kario(Jichi Medical University)
Speaker: Hideo Inaba(Department of Emergency and Critical Care Medicine, Kanazawa University)
Akihiko Takahashi(Sakurakai Takahashi Hospital)
Kazuhiko Hanzawa(Thoracic and Cardiovascular Surgery, Niigata University)
Seiji Hokimoto(Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University)
Jun Takahashi(Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine)
Satoshi Yasuda(National Cerebral and Cardiovascular Center)
(13)How to Enhance the Intravascular Ultrasound in Future

March 19 (Sun) 16:40-18:10

Room15(Hotel Kanazawa, 4F, Emerald AB)

Chairperson: Paul Schoenhagen(Cleveland Clinic, USA)
Takashi Akasaka(Wakayama Medical University)
Speaker: Isao Mori(Interventional Systems Business, Terumo Corporation)
Mitsuyasu Terashima(Toyohashi Heart Center)
Takashi Kubo(Wakayama Medical University)
Hitoshi Matsuo(Department of Cardiovascular Medicine, Gifu Heart Center)
Teruo Noguchi(Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center)
Nobuhiro Tahara(Division of Cardiovascular Medicine, Kurume University School of Medicine)

Plenary Sessions

(1)Future Perspective on Diagnoses and Therapies for Dyslipidemia

March 17 (Fri) 11:30-13:00

Room15(Hotel Kanazawa, 4F, Emerald AB)

Chairperson: Ken-ichi Hirata(Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe)
Evan A. Stein(Metabolic and Atherosclerosis Research Center, USA)
State-of-the Art: Evan A. Stein(Metabolic and Atherosclerosis Research Center, USA)
Speaker: Yu Kataoka(Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center)
Masa-aki Kawashiri(Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine)
Shinji Koba(Division of Cardiology, Showa University School of Medicine)
Tatsuro Ishida(Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine)
Plenary Sessions 〈English〉
(1) Future Perspective on Diagnoses and Therapies for Dyslipidemia
Chairperson: Ken-ichi Hirata(Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe)
Evan Albert Stein(Metabolic and Atherosclerosis Research Center, USA)

Atherosclerotic cardiovascular disease (CVD) is the leading cause of mortality. Dyslipidemia is an important risk factor to target in both the primary and secondary prevention of CVD. Reducing plasma low-density lipoprotein cholesterol (LDL-C) by statin has achieved risk reduction of cardiovascular events. However, despite optimal statin therapy, more than half of cardiovascular events cannot be prevented. Recently, inhibition of PCSK9 by monoclonal antibodies has achieved strong reductions in LDL-C levels. Clinical evidences will be needed to evaluate whether PCSK9 inhibition yields benefits on cardiovascular endpoints for patients with high-risk CV patients including familial hypercholesterolemia. In contrast to LDL-C reducing therapy, the clinical efficacy of raising plasma HDL-C levels to achieve cardiovascular risk reduction has been difficult to prove. Recently published clinical trials involving the addition of niacin or CETP inhibitors failed to prove clinical benefit despite significantly increasing the HDL-C. From these results the function of HDL and fatty acids are highlighted for assessing risk or response to therapies targeted at HDL. The reliable assay systems to evaluate the functions of lipoproteins or lipids will be needed to predict cardiovascular events and to assess efficacies of drugs in dyslipidemic patients. In addition, development of new drugs for dyslipidemia and anti-inflammatory therapies for atherosclerosis will be required to reduce cardiovascular events. In this plenary session, we will discuss about future perspective on diagnoses and therapies for dyslipidemia.

(2)Challenges for Elucidating the Pathogenesis of Heart Failure~From Genome to Organs~

March 17 (Fri) 17:00-18:30

Room1(Ishikawa Ongakudo, 2F, Concert Hall)

Chairperson: Hiroyuki Tsutsui(Department of Cardiovascular Medicine, Kyushu University)
Kinya Otsu(King's College London, UK)
State-of-the Art: Kinya Otsu(King's College London, UK)
Speaker: Finn Waagstein(Sahlgrenska University Hospital, Sweden)
Osamu Yamaguchi(Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine)
Youji Nagata(Division of Cardiology, Kanazawa University Graduate School of Medicine)
Tsunenori Saito(Department of Cardiovascular Medicine, Nippon Medical School)
Shouji Matsushima(Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Science)
Plenary Sessions 〈English〉
(2) Challenges for Elucidating the Pathogenesis of Heart Failure~From Genome to Organs~
Chairperson: Hiroyuki Tsutsui(Department of Cardiovascular Medicine, Kyushu University)
Kinya Otsu(King's College London, UK)

Heart failure (HF) is a complex clinical syndrome that can result from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood. HF is a leading cause of morbidity and mortality in industrialized countries and is also a growing public health problem, mainly because of aging of the population. The basic research at the genomic, molecular, cellular, and organ levels has elucidated the pathophysiology of HF. The basis of HF is “myocardial remodeling”, which includes the structural and functional abnormalities in the contractile apparatus and intracellular Ca handling within cardiac myocytes and extracellular matrix. Neurohumoral factors as well as inflammation and oxidative stress are involved in the process of maladaptive remodeling and various signaling molecules mediate the cellular proliferation, cell death, and protein degradation. Based on the findings from the basic research, the modern therapeutic strategy for HF has been developed. However, its efficacy is still limited. This plenary session is planned to overview the recent understanding regarding the pathogenesis of HF and focus on the future perspectives for novel therapeutic target.

(3)Late Complications after Repair in Adult Congenital Heart Disease

March 18 (Sat) 17:20-18:50

Room1(Ishikawa Ongakudo, 2F, Concert Hall)

Chairperson: Koichiro Niwa(Cardiovascular Center, St. Luke's International Hospital)
Jamil Aboulhosn(Ronald Reagan UCLA Medical Center, USA)
State-of-the Art: Jamil Aboulhosn(Ronald Reagan UCLA Medical Center, USA)
Speaker: Hiroki Mori(Department of Pediatric Cardiology,Tokyo Women's Medical University)
Takeshi Tsuda(Nemours/Alfred I. duPont Hospital for Children, USA)
Shunsuke Tatebe(Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine)
Daiji Takeuchi(Department of Pediatric Cardiology,Tokyo Women's Medical University)
Yuji Naito(Department of Home Care Medicine, Yumino Heart Clinic)
Plenary Sessions 〈English〉
(3) Late Complications after Repair in Adult Congenital Heart Disease
Chairperson: Koichiro Niwa(Cardiovascular Center, St. Luke's International Hospital)
Jamil Aboulhosn(Ronald Reagan UCLA Medical Center, USA)

In most of the adult congenital heart disease patients, cardiovascular surgery was performed during childhood. QOL in these patients during childhood is fair, but with advancing age, late complication can develop. Sometime reoperation becomes necessary.
Surgery for congenital heart disease is not a radical, and residua and sequellae can be happens after surgery. Even if proper surgery was performed, disease or operative method specific anatomical and functional abnormalities develop with age and can induce cardiac failure and arrhythmias. In tetralogy of Fallot, residual right ventricular outflow tract stenosis is a residua and pulmonary valve regurgitation, which is inevitably happens after valvotomy, is a sequellae. These long lasting residua and sequellae induce late complications such as cardiac failure, arrhythmias, pulmonary hypertension, thromboembolic events and aortopathy, etc. Pathophysiology and clinical findings of cardiac failure in with congenital heart disease (ACHD) are similar to that observed in acquired cardiac disease. ACHD is a chronic cardiac failure syndrome. Right ventricular failure, either sub-pulmonary or systemic, is a remarkable finding in ACHD. However, management of cardiac failure has not been established. With time, operative scare, artificial materials, specific hemodynamics in each congenital heart disease and complicated cardiac failure have been the cause of arrhythmias in ACHD, and arrhythmias are one of the important late complications. Supraventricular tachy- and brady-arrhythmias are popular and become major morbidity for ACHD. Also, pregnancy and delivery, employment, psychosocial issues are important problems to be handled in ACHD. Therefore, meticulous regular follow-up is necessary in ACHD. In this symposium, we will be focusing on these long-term complications regarding pathophysiology, current status and recent management in ACHD patients.

(4)Medical and Healthcare Plan for Cardiovascular Diseases in Aging Population with Decreasing Birthrate

March 18 (Sat) 17:20-18:50

Room6(Hotel Nikko Kanazawa, 3F, Kujaku A)

Chairperson: Tomoyuki Takura(Department of Health Economics and Industrial Policy, Osaka University Graduate School of Medicine)
Masatsugu Hori(Osaka Medical Center for Cancer and Cardiovascular Diseases)
Speaker: Takayuki Matsuki (Steel Memorial Muroran Hospital)
Mayu Nishio(Department of Cardiology, Saiseikai Senri Hospital)
Eisaku Nakane(Cardiovascular Center, Kitano Hospital, The Tazuke Kofukai Medical Research Institute)
Noboru Watanabe(Division of Cardiovascular medicine, Hokushin General Hospital)
Masami Sakoi(Ministry of Health, Labour and Welfare)
Plenary Sessions 〈Japanese〉
(4) Medical and Healthcare Plan for Cardiovascular Diseases in Aging Population with Decreasing Birthrate
Chairperson: Tomoyuki Takura(Department of Health Economics and Industrial Policy, Osaka University Graduate School of Medicine)
Masatsugu Hori(Osaka Medical Center for Cancer and Cardiovascular Diseases)

Aging of the population and declining birthrates represent ongoing trends in Japan, ahead of those in various other advanced countries. The population peaked in 2008, and has since steadily decreased. As a result, the gap between medical spending for the elderly, i.e. those age 75 and older, of approximately \13 trillion in FY2013 (accounting for 32.7% of the national health expenditure, up 3.7% from the previous year), and the real economy that supports it (nominal GDP: up 0.0% year-on-year) continues to expand. With the aging of society, moreover, disease proportions have also changed. Cardiovascular diseases have increased in share as the cause of death, accounting for 26.8% of total deaths, with 15.5% being due to heart diseases and 9.0%, to cerebrovascular diseases. To reduce the social burden with diseases, the establishment of the healthy life expectancy is indispensable. A notable obstacle for this purpose is the increase in chronic heart failure and stroke wherein patients suffer multiple hospital cares, and their disease courses are hampered by diverse cares of exacerbating factors as well. With the 2025 problem looming ever closer, we are facing to the emergence of other difficult issues, including an increased prevalence of the elderly living alone and of seniors cared by other elderlies. Given these background factors, the Japanese government launched the Community Care Initiative and the Integrated Community Care System, and has been working to revise laws relating to the medical insurance system. In view of the above, the cardiovascular disease sector is being called upon, going forward, to switch to a durable system of making effective use of finite medical resources, all the while promoting progress in medicine, encouraging the new medical technologies. To make these innovations possible, we must consider a medical supply system that meets characteristic regional needs and the real world practice of healthcare while making use of multidisciplinary team medicine and functional collaborations. In this session, therefore, we will discuss the medical and healthcare plans for cardiovascular diseases, focusing on the future vision of medical resources and supply system and the effective disease management in keeping mind the harmonization with the social economy in the aging society.

(5)Action Plan for “202030”
(※Partly in English)

March 19 (Sun) 08:30-10:00

Room1(Ishikawa Ongakudo, 2F, Concert Hall)

Chairperson: Keiko Takihara(Health Care Center, Osaka University)
Toyoaki Murohara(Department of Cardiology, Nagoya University Graduate School of Medicine)
Keynote Lecture: Christine E. Seidman(Harvard Medical School, USA)
Speaker: Talia H. Swartz(Icahn School of Medicine at Mount Sinai, USA)
Keiko Shimokata(Denso Corporation)
Discussion: Yasuko Bando(Department of Cardiology, Nagoya University Graduate School of Medicine)
Hiromi Yanagisawa(Life Science Center of Tsukuba Advanced Research Alliance (TARA Center), University of Tsukuba)
Plenary Sessions 〈Japanese(Partly in English)〉
(5) Action Plan for “202030”
Chairperson: Keiko Takihara(Health Care Center, Osaka University)
Toyoaki Murohara(Department of Cardiology, Nagoya University Graduate School of Medicine)

The Japanese government will oblige companies by a law to appoint more female managers (at least 30%) by 2020, which is known as an action plan “202030”. The obligation will encourage women play a greater role in the society and economy, which is called “womenomics”. In this plenary session, we expect an educational lecture by Professor C. E. Seidman at the Department of Genetics and Medicine, Harvard Medical School regarding the history of the roles of women in the American Heart Association. In addition, we invite leading speakers from the government and industrial agency for the extensive discussion of the “womanomics”. We hope that this session will facilitate the action plan “202030” in the Japanese Circulation Society.

(6)Science Policy for Cardiovascular Medical Research and Development in Japan

March 19 (Sun) 11:10-12:40

Room1(Ishikawa Ongakudo, 2F, Concert Hall)

Chairperson: Ryozo Nagai(Jichi Medical University)
Hiroaki Shimokawa(Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine)
Speaker: Hiromichi Matsuo(Japan Agency for Medical Research and Development)
Katsuhiko Hara(Ministry of Education, Culture, Sports, Science and Technology)
Ayako Nakamura(Ministry of Health, Labour and Welfare)
Yoichiro Kono(Ministry of Economy, Trade and Industry)
Noriatsu Kono(Pharmaceuticals and Medical Devices Agency)
Plenary Sessions 〈Japanese〉
(6) Science Policy for Cardiovascular Medical Research and Development in Japan
Chairperson: Ryozo Nagai(Jichi Medical University)
Hiroaki Shimokawa(Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine)

Japan is the first country that reached the super-aged society in the world and its high aging rate is also predicted to be continued in the future. In this super-aged society, the importance of cardiovascular diseases has been increasing more and more, while the medical cost for cardiovascular diseases also accounts for ~20% of the total cost in Japan. Although it is important to translate basic and preclinical research achievements into clinical research and practice to promote national welfare and economy, such translation was poorly made despite the high level of basic research in Japan, due to the insufficient supporting system. As a result, Japanese patients had less chance to benefit from the medical progress than western patients and Japan has also been suffering from the excess of imports over exports of medical drugs and devices for a long time. At present, a significant progress has been made in the medical industry with the resultant global and tough competition. Thus, the support by the Japanese government of the medical research and development is an urgent matter. Based on these circumstances, the Japan Agency for Medical Research and Development (AMED) was founded in 2015, where medical research and development by the three ministries (Ministry of Education, Culture, Sports, Science and Technology, MEXT; Ministry of Health, Labour, MHLW; and Welfare and Ministry of Economy, Trade and Industry, METI) have been merged. In this plenary session, experts from MEXT, MHLW, AMED and pharmaceutical and device agency (PMDA) will discuss the current situation and future perspectives for cardiovascular medical research and development in Japan.

(7)What is the Best Imaging Modality for Less Invasive Treatment of Structural Heart Diseases

March 19 (Sun) 11:10-12:40

Room2(Ishikawa Ongakudo, 2F, Hogaku Hall)

Chairperson: Satoshi Nakatani(Department of Functional Diagnostics, Osaka University Graduate School of Medicine)
Paul Schoenhagen(Cleveland Clinic, USA)
State-of-the Art: Paul Schoenhagen(Cleveland Clinic, USA)
Speaker: Pravin M. Shah(Hoag Heart Institute, USA)
Shunpei Mori(Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine)
Takuya Hasegawa(Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center)
Yoko Horibata(Division of Cardiology, Cardiovascular Center, Saiseikai Kumamoto Hospital)
Akihisa Kataoka(Department of Cardiology, Teikyo University)
Yuji Itabashi(Department of Cardiology, Keio University School of Medicine)
Plenary Sessions 〈English〉
(7) What is the Best Imaging Modality for Less Invasive Treatment of Structural Heart Diseases
Chairperson: Satoshi Nakatani(Department of Functional Diagnostics, Osaka University Graduate School of Medicine)
Paul Schoenhagen(Cleveland Clinic, USA)

Various imaging modalities have been developed and used for catheter intervention for structural heart disease (SHD) including transcatheter aortic valve implantation (TAVI), MitraClip, atrial septal occlusion, paravalvular leak closure and left atrial appendage occlusion. Imaging modalities are important as a tool for not only pre-procedural diagnosis and post-procedural evaluation but also intra-procedural monitoring. Which imaging modality is the best? Should we use multiple modalities in one procedure in a mutually complementary manner? What are the pitfalls in each modality? Are there any emerging modalities? Through discussion, we anticipate to answer these questions.

(8)Clinical Researches with Big Data in Japan

March 19 (Sun) 11:10-12:40

Room11(Kanazawa Miyako Hotel, 7F, Hoh-Oh)

Chairperson: Yoshihiko Saito(First Department of Internal Medicine, Nara Medical University)
Hisao Ogawa(Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center)
Speaker: Yoko Nakao(Department of Preventive Medicine and Epidemiologic Informatics, National Cerebral and Cardiovascular Center)
Takehiro Kimura(Department of Cardiology, Keio University School of Medicine)
Michihiro Yoshimura(Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine)
Shungo Hikoso(Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine)
Takashi Shirato(Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine)
Satoshi Yasuda(National Cerebral and Cardiovascular Center)
Plenary Sessions 〈Japanese〉
(8) Clinical Researches with Big Data in Japan
Chairperson: Yoshihiko Saito(First Department of Internal Medicine, Nara Medical University)
Hisao Ogawa(Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center)

In medical research, the objectives, subjects, and methods have changed accordance with changing social and medical needs and technique, which could be applied to. In earlier times, infections were major fatal disorders, subsequently stroke became the leading cause of death, and currently, malignancies have been substituted in Japan. Along with this, the research institutes for tuberculosis, stroke and cancer have been established, which have contributed to the prevention and management of these life-threatening diseases. In the last two decades, great advances have been made in the field of molecular biology, and novel computing techniques have resulted in significant improvements in the quality and quantity of medical research.
Currently, Japan has become a super-aged society, and the extension of healthy life expectancy, as opposed to life span, is widely recognized as an important issue. In other words, better quality medical-care has been recognized as critical to better quality of life (QOL) or quality of death (QOD). Given the high morbidity and mortality rates of cardiovascular diseases, research that leads to better medical care of cardiovascular diseases are necessary. However, the evidence put forth by earlier randomized controlled trials, in which substantial portions of study population were excluded because of their age or comorbidities, was not applicable to all real world populations. In this context, we are willing to develop new research style, wherein the endpoints are QOL or QOD rather than life span, that ideally includes every old patient with co-morbidities from all over Japan.
Nowadays, with the significant advancements in computer science, it is possible to deal with big data in the medical science. In fact, the Ministry of Health and Labour and Welfare maintains the new National Database (NDB), and all surgeons registered all their operations in the National Clinical Database (NCD). Moreover, the Japanese Circulation Society has also developed big databases named the JROAD or JROAD-DPC.
In this symposium, we hope to discuss the current status and future directions of research using big data.

(9)Management of Pregnancy and Delivery in Women with Heart Disease
(※Partly in English)

March 19 (Sun) 14:00-15:30

Room1(Ishikawa Ongakudo, 2F, Concert Hall)

Chairperson: Teiji Akagi(Cardiac Intensive Care Unit, Okayama University)
Tomoaki Ikeda(Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine)
Speaker: Candice K. Silversides(University of Toronto, Canada)
Masafumi Nii(Department of Obstetrics and Gynecology, Mie University Hospital)
Jota Maki(Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences)
Gen Harada(Department of Pediatric Cardiology,Tokyo Women's Medical University)
Ichiro Sakamoto(Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences)
Plenary Sessions 〈Japanese(Partly in English)〉
(9) Management of Pregnancy and Delivery in Women with Heart Disease
Chairperson: Teiji Akagi(Cardiac Intensive Care Unit, Okayama University)
Tomoaki Ikeda(Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine)

Management of pregnancy and delivery is the important clinical issue for the practice of adult congenital heart disease. Hemodynamic or hematological changes during pregnancy or delivery significantly influence on their hemodynamic condition, may cause of life-threatening events if patients complicated with certain cardiovascular comorbidities or sequelae. Currently, pregnant women with heart disease account for 1% of total pregnant women, in addition, the proportion increases to 2 to 3% when cardiovascular diseases such as arrhythmia are included. Cardiovascular diseases is the 4th leading preventable cause of death in pregnant women in Japan. Although Japanese Circulation Society Guidelines “Indication and Management of Pregnancy and Delivery in Women with Heart Disease” has been established in 2010, the individual medical management performed based on the agreement among experienced physicians or limited experienced. This is due to the number of pregnancy in each hear condition is still small and the presence of ethically difficulties for conducting control study. Pregnancy, which had not been experienced in the past such as Fontan circulation, is going to be a big clinical issue.
In this session, we would like to discuss about the current issues and future direction of optimal management system for pregnant women with heart disease, from the various point view from obstetrician and gynecologists, pediatric cardiologists and adult cardiologists. We are highly expecting that this session contributes the establishment of the optimal management system for women with heart disease.

(10)Advance in Assessment and Treatment of Valvular Heart Diseases

March 19 (Sun) 14:00-15:30

Room2(Ishikawa Ongakudo, 2F, Hogaku Hall)

Chairperson: Kazuhiro Yamamoto(Tottori University)
Thierry Lefevre(Institut Hospitalier Jacques Carier, France)
State-of-the Art: Thierry Lefevre(Institut Hospitalier Jacques Carier, France)
Speaker: Makoto Amaki(National Cerebral and Cardiovascular Center)
Yasuhiro Ichibori(Department of Cardiology, Osaka University Graduate School of Medicine)
Hiroto Utsunomiya(Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences)
Shunsuke Kubo(Department of Cardiology, Kurashiki Central Hospital)
Hidehiro Kaneko(Department of Cardiology, Heart Center Brandenburg, Germany)
Plenary Sessions 〈English〉
(10) Advance in Assessment and Treatment of Valvular Heart Diseases
Chairperson: Kazuhiro Yamamoto(Tottori University)
Thierry Lefevre(Institut Hospitalier Jacques Carier, France)

Degenerative aortic stenosis and functional mitral regurgitation are major components of structural heart disease. Recently, secondary tricuspid regurgitation due to dilatation and/or dysfunction of right-side heart is notified as an important determinant of the pathophysiology of cardiovascular diseases. These valvular diseases provide various phenotypes, and their assessment is advanced. In diagnostic imaging, detailed evaluation of cardiac function, tissue characterization of myocardial tissue and the assessment of stress-induced changes in valvular regurgitation or stenosis are conducted in addition to the quantitative estimation of valvular regurgitation or stenosis at rest to decide the therapeutic strategy and to predict the efficiency of the interventions. The less invasive therapy such as TAVR and MitraClip has been developed for patients with valvular heart diseases at high operative risks and has been introduced in Japan. Many patients have already undergone TAVR in Japan, and its advantages and points to note have been shared. In addition to device therapy, we have to establish the therapeutic strategy against the pathophysiology which has not necessarily been a therapeutic target with invasive therapy. Currently, the operation of tricuspid regurgitation alone is an issue under discussion.
In this session, we wish the participants to discuss recent advance in assessment and treatment of valvular heart diseases.

Symposia

(1)Management and Treatment of Heart Failure in ‘Super-aged Society’
(※Partly in English)

March 17 (Fri) 8:50-10:20

Room1(Ishikawa Ongakudo, 2F, Concert Hall)

Chairperson: Masafumi Kitakaze(Department of Clinical Medicine and Development, National Cerebral and Cardiovascular Center)
Ichiro Shiojima(Department of Medicine II, Kansai Medical University)
Keynote Lecturer: Piotr Ponikowski(Military Hospital, Poland)
Speaker: Jun Takahashi(Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine)
Yoko Miyasaka(Department of Medicine II, Kansai Medical University)
Jun Tanaka(Division of Cardiology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology)
Takashi Yokota(Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine)
Dai Yumino(Department of Home Care Medicine, Yumino Heart Clinic)
Hiroki Fukuda(National Cerebral and Cardiovascular Center)
Symposia 〈Japanese〉
(1) Management and Treatment of Heart Failure in ‘Super-aged Society’
Chairperson: Masafumi Kitakaze(Department of Clinical Medicine and Development, National Cerebral and Cardiovascular Center)
Ichiro Shiojima(Department of Medicine II, Kansai Medical University)

Both incidence and prevalence of chronic heart failure increase along with aging. Japan meets the criteria of ‘super-aged society’ in which more than 20% of the general population are people 65 years and older, and the number of elderly patients with heart failure is expected to increase significantly because of the rapid aging of the population. Heart failure in the elderly is characterized by comorbidities of other organs, repeated hospitalization due to decompensated acute heart failure, and increased risk of complications with pharmacological and/or non-pharmacological treatments. Heart failure with preserved ejection fraction (HEpEF) is also recognized as a disease of older population. Moreover, it should be noted that the clinical evidence of older patients, especially those >75 years of age, are underrepresented in most of the major clinical trials and therefore the results of those studies may not be generalized to elderly patients. The topics of heart failure in the elderly include but are not restricted to the primary prevention of heart failure, the therapeutic strategies in the acute versus chronic phase of heart failure, multidisciplinary care for heart failure through interprofessional collaboration as team medical care, and palliative care in end-stage heart failure. In this symposium, we will discuss how to manage and treat elderly patients with heart failure from multiple viewpoints.

(2)Vascular Biology as Interactive Science of Cardiovascular Disease

March 17 (Fri) 8:50-10:20

Room5(Hotel Nikko Kanazawa, 3F, Kujaku BC)

Chairperson: Masahiko Kurabayashi(Department of Medicine and Biological Science, Gunma University Graduate School of Medicine)
Takahisa Nakamura(Cincinnati Children's Hospital, USA)
Keynote Lecture: Takahisa Nakamura(Cincinnati Children's Hospital, USA)
Speaker: Kimio Satoh(Department of Cardiovascular Medicine, Tohoku University, Graduate School of Medicine)
Tatsuya Iso(Department of Medicine and Biological Science, Gunma University, Graduate School of Medicine)
Ichiro Manabe(Department of Aging Research, Chiba University Graduate School of Medicine)
Norihiko Takeda(Deaprtment of Cardiovasular Medicine, Graduate School of Medicine, The University of Tokyo)
Yasuhiro Izumiya(Department of Cardiovascular Medicine, Kumamoto University)
Symposia 〈English〉
(2) Vascular Biology as Interactive Science of Cardiovascular Disease
Chairperson: Masahiko Kurabayashi(Department of Medicine and Biological Science, Gunma University Graduate School of Medicine)
Takahisa Nakamura(Cincinnati Children's Hospital, USA)

Historically, in the late 1970s, Russel Ross proposed the concept of atherosclerosis as a response of the arterial wall to injury by highlighting the importance of smooth muscle (SMC) proliferation. Subsequent studies from Libby and Hansson in late 1990s demonstrated a major role of a complex interaction between risk factors and inflammation rather in the disease progression. A concept of atherosclerosis as inflammation has consistently been verified by accumulated numerous clinical studies, including imaging and intravascular ultrasound studies directed by Nissen and Fuster, epidemiological studies by Levy, and pathological studies by Virmani.

To date, there have been many outstanding discoveries in cardiovascular medicine, including LDL-receptor by Goldstein and Brown, statins by Endo, endothelin by Yanagisawa, nitric oxide (NO) by Furchgott and Ignarro. It is not to mention that these studies are outstanding particularly because of remarkable contribution to the clinical medicine. These discoveries greatly help us to understand the unrecognized pathophysiology of cardiovascular disease and help to develop the new drugs to reduce mortality and morbidity of many patients. In this symposium, we like to discuss about the novel discoveries achieved by forefront research in a wide range of vascular medicine, including atherosclerosis, physiological and pathological angiogenesis, molecular mechanism of pulmonary hypertension, aneurysm, diabetes- and related metabolic disease etc., which could have important relevance to cardiovascular disease.

(3)Current Status and Future Perspective of Management for the Patient with Critical Limb Ischemia

March 17 (Fri) 8:50-10:20

Room15(Hotel Kanazawa, 4F, Emerald AB)

Chairperson: Kimihiro Komori(Department of Vascular Surgery, Nagoya University Graduate School of Medicine)
Hiroyoshi Yokoi(Cardiovascular Center, Fukuoka Sanno Hospital)
Speaker: Yukihito Higashi(Department of Cardiovascular Regeneration and Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University)
Nobuyoshi Azuma(Division of Vascular Surgery, Asahikawa Medical University)
Tatsuya Shiraki(Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine)
Osami Kawarada(Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center)
Shin Okamoto(Kansai Rosai Hospital Cardiovascular Center)
Ryoichi Kyuragi(Department of Vascular Surgery, Kyushu Medical Center)
Tatsuya Nakama(Miyazaki Medical Association Hospital, Cardiovascular Center)
Symposia 〈Japanese〉
(3) Current Status and Future Perspective of Management for the Patient with Critical Limb Ischemia
Chairperson: Kimihiro Komori(Department of Vascular Surgery, Nagoya University Graduate School of Medicine)
Hiroyoshi Yokoi(Cardiovascular Center, Fukuoka Sanno Hospital)

Increases in diabetes and chronic kidney disease have led to increases in critical limb ischemia (CLI), the most serious type of lower limb occlusive atherosclerosis. CLI, the treatment structure for which is not as clearly established as those for cerebral and myocardial infarctions, has poorer prognoses, adds pressure to healthcare costs and is becoming a worldwide issue. Japan has many dialysis patients, who run a higher risk of developing CLI; unfortunately, here in Japan we do not have foot specialists like other countries. As a result, diagnosis is often delayed, and doctors must treat very difficult cases.

Some ten years ago, doctors here in Japan began performing endovascular interventions, with cardiologists, vascular surgeons and plastic surgeons providing multidisciplinary treatment, and sharing evidence regarding limb salvage. In March of this year, the Japan Circulation Society published revised 2015 guidelines on peripheral occlusive arterial disease treatment. Meanwhile, next-generation device assessment indicators were created for new devices to treat CLI, and Japanese centers are taking part in global trials.

In this session, we will look at current CLI treatment results in Japan; hear about evolving CLI diagnostic testing, the latest endovascular technology and devices, new treatment strategies, new trial designs and trial results; and discuss the most suitable treatment system for CLI patients in Japan.

We look forward to hearing from many of our fellow physicians who are treating CLI patients.

(4)Vascular Problem in Long-term after Kawasaki Disease

March 18 (Sat) 8:30-10:00

Room6(Hotel Nikko Kanazawa, 3F, Kujaku A)

Chairperson: Takafumi Ueno(Center of Cardio-vascular Disease, Kurume University)
Masahiro Ishii(Department of Pediatrics, School of Medicine, Kitasato University)
Speaker: Toru Miyoshi(Department of Cardiology, Ehime Prefectural Imabari Hospital)
Shota Okuno(Kansai Rosai Hospital Cardiovascular Center)
Nobuhiro Tahara(Division of Cardiovascular Medicine, Kurume University School of Medicine)
Yasuhide Asaumi(Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Centre)
Manabu Matsumoto(Department of Pathology, National Cerebral and Cardiovascular Center)
Hiroyuki Ohashi(Department of Pediatrics, Mie University Graduate School of Medicine)
Symposia 〈Japanese〉
(4) Vascular Problem in Long-term after Kawasaki Disease
Chairperson: Takafumi Ueno(Center of Cardio-vascular Disease, Kurume University)
Masahiro Ishii(Department of Pediatrics, School of Medicine, Kitasato University)

Professor Tomisaku Kawasaki discovered Kawasaki disease in 1967, almost 50 years ago. Progress made in treatment methods during the acute phase of the disease has reduced the incidence of cardio vascular complication from 25% to 3%. It has also been reported that between 100-200 patients per year contract Kawasaki disease as part of acute coronary syndrome (ACS) in adult patients. The many children to have experienced Kawasaki disease are now at the age where they are susceptible to arterial sclerosis. It is still unclear, however, to what extent the experience of extreme inflammation of the blood vessels throughout the body in early childhood impacts the blood vessels of the body in the long term. Furthermore, around 50% of coronary artery aneurisms occurring as a result of Kawasaki disease are naturally regressed. This phenomenon is known as “regression”, but reports suggest that these coronary arteries are extremely close to the condition observed in the early stages of arterial sclerosis. No study has yet been done on subsequent progression, however. Furthermore, it is still unclear whether or not cases in which coronary artery aneurisms remain in the body are at an increased risk for developing arterial sclerosis. Recently, progress in imaging diagnostics has allowed coronary catheters to be used to capture images of blood vessels, while vascular ultrasound, intravascular ultrasound (IVUS), optical coherence tomography (OCT), computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET), among other technologies, allow evaluation of lesions within the blood vessels. This session will present a discussion on vascular lesions between various diverse people working areas related to the long-term management of Kawasaki disease, such as pediatricians, cardiologists, cardiovascular specialists etc.

(5)New Development of Cardiovascular Regenerative Medicine

March 18 (Sat) 8:30-10:00

Room12(Kanazawa Miyako Hotel, 7F, Hishoh)

Chairperson: Shinya Minatoguchi(Department of Cardiology, Gifu University)
Michael Schneider(Imperial College London, UK)
Keynote Lecture: Michael Schneider(Imperial College London, UK)
Speaker: Shinya Minatoguchi(Department of Cardiology, Gifu University)
Takayuki Asahara(Institute of Medical Sciences, Tokai University)
Satsuki Fukushima(Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine)
Masaki Ieda(Department of Cardiology, Keio University School of Medicine)
Symposia 〈English〉
(5) New Development of Cardiovascular Regenerative Medicine
Chairperson: Shinya Minatoguchi(Department of Cardiology, Gifu University Graduate School of Medicine)
Michael Schneider(Imperial College London, UK)

Heart failure is one of the leading causes of morbidity and mortality. Heart failure is usually caused by the loss of large number of cardiomyocytes which leads to the development of left ventricular (LV) remodeling which is induced by cardiovascular disease such as acute myocardial infarction or cardiomyopathy. The fundamental treatment of heart failure is the regeneration of cardiac tissues such as cardiomyocytes and vasculature. Therefore, novel and advanced therapies have to be developed to regenerate cardiomyocytes and vasculature and prevent LV remodeling and heart failure and to improve long-term prognosis of heart failure. The method to regenerate cardiac tissues may include ES cell, iPS cell, direct reprogramming, somatic stem cells, micro RNAs, cytokines and so on. In this symposium, novel and translational regenerative medicine against heart failure will be discussed.

(6)Cardiomyopathies: A Diagnostic and Therapeutic Update

March 18 (Sat) 8:30-10:00

Room14(Hotel Kanazawa, 2F, Diamond C)

Chairperson: Hiroaki Kitaoka(Department of Cardiology, Neurology and Aging Science, Kochi University)
Diane Fatkin(Victor Chang Cardiac Research Institute, Australia)
Keynote Lecture: Diane Fatkin(Victor Chang Cardiac Research Institute, Australia)
Speaker: Toru Kubo(Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University)
Kengo Kusano(Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center)
Yuko Wada(Department of Cardiovascular Medicine, Shiga University of Medical Science)
Takayuki Inomata(Department of Cardiovascular Medicine, Kitasato Institute Hospital)
Yoshitaka Iwanaga(Division of Cardiology, Kindai University)
Rie Aoyama(Department of Cardiovascular Medicine, Nippon Medical School)
Ryota Teramoto(Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine)
Symposia 〈Japanese〉
(6) Cardiomyopathies: A Diagnostic and Therapeutic Update
Chairperson: Hiroaki Kitaoka(Department of Cardiology, Neurology and Aging Science, Kochi University)
Diane Fatkin(Victor Chang Cardiac Research Institute, Australia)

The concept and definition of cardiomyopathy has been change with the times. It has been with in the 'cause unknown' myocardial disease in the past. However, as the understanding of the pathogenesis caused by gene analysis and the assessment in the morphology according with the evolution of imaging modality such as cardiac MRI have been evolved, cardiomyopathy has not been 'cause unknown' myocardial disease. There are two current classification of cardiomyopathy from the American Heart Association (2006) and the European Society of Cardiology (2008) from each own point of view. Dilated cardiomyopathy, hypertrophic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy are common in the clinical setting and gene analysis and non-pharmacological therapy such as devices and percutaneous transluminal septal myocardial ablation have also been advanced. However, the relationship between the gene mutation and myocardial dysfunction is not solved and the actual circumstances of non-pharmacological therapy is not necessarily apparent in Japan. In addition, it has been an increasing number of experience of the secondary cardiomyopathy, such as cardiac sarcoidosis and cardiac Fabry disease.

Therefore, in this symposium, the new findings in the elucidation of the pathogenesis and the progress of the treatment in primary and secondary cardiomyopathies will be announced from the latest point of view in the gene analysis, diagnostic imaging and the registry in Japan.

We would like to discuss the prospects to the future of cardiomyopathy research and medical care.

(7)Bioresorbable Vascular Scaffold: Current Status and Future Expectation

March 18 (Sat) 11:10-12:40

Room5(Hotel Nikko Kanazawa, 3F, Kujaku BC)

Chairperson: Masato Nakamura(Toho University, Ohashi Medical Center)
Marco Roffi(University Hospital, Switzerland)
Speaker: Fumiyuki Otsuka(National Cerebral and Cardiovascular Center)
Akihito Tanaka(Interventional Cardiology Unit, San Raffaele Scientific Institute, Italy)
Yuki Ishibashi(St. Marianna University School of Medicine)
Takashi Kajiya(Department of Cardiology, Tenyoukai Central Hospital)
Amr Hassan Mostafa(Cairo University, Egypt)
Symposia 〈English〉
(7) Bioresorbable Vascular Scaffold: Current Status and Future Expectation
Chairperson: Masato Nakamura(Toho University, Ohashi Medical Center)
Marco Roffi(University Hospital, Switzerland)

The percutaneous coronary intervention (PCI) has greatly improved by introduction of the second generation drug elution-related stent(DES). The risk of the stent thrombosis at late phase was considerably decreased. In addition, the standard deviation of angiographic late lumen loss becomes small remarkably. Now, we can expect the long-term outcomes following PCI. It is a reason to be said that current status of PCI is a period of maturity of PCI. On top of that, as for PCI, further progress is expected. The most influential candidate is bioresorbable vascular scaffold (BRS). The PCI accomplished progress mainly on a stent base, but is the device of totally different concepts. Because the prospective merit will be a long-term effect on coronary artery, we have not globally yet understood the possibility of BRS enough. This device is expected to be approved in japan this year, and it is supposed that some of initial results becomes clear when this session is carried out. I want to think about current status and future expectation regarding BRS, and also how you introduce an unknown device into this country.

(8)New Therapy for Uncontrollable Hypertension
(※Partly in English)

March 18 (Sat) 11:10-12:40

Room6(Hotel Nikko Kanazawa, 3F, Kujaku A)

Chairperson: Jitsuo Higaki(Department of Cardiology, Pulmonology, Hypertension and Nephrology, Ehime University Graduate School of Medicine)
Ryuichi Morishita(Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine)
Keynote Lecture: Murray Esler(Baker IDI Heart and Diabetes Institute, Australia)
Speaker: Hisayoshi Murai(Department of System Biology, Kanazawa University Graduate School of Advanced Preventive Medical Science)
Hisakazu Ogita(Department of Biochemistry and Molecular Biology, Shiga University of Medical Science)
Hiroshi Koriyama(Department of Health Development and Medicine, Osaka University Graduate School of Medicine)
Kazuki Shiina(Department of Cardiology, Tokyo Medical University)
Symposia 〈Japanese〉
(8) New Therapy for Uncontrollable Hypertension
Chairperson: Jitsuo Higaki(Department of Cardiology, Pulmonology, Hypertension and Nephrology, Ehime University Graduate School of Medicine)
Ryuichi Morishita(Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine)

 Hypertension treatment has been advanced from single treatment with various anti-hypertensive drugs to combination tablets, in order to consider the adherence of anti-hypertensive drugs. However, there are still the uncontrollable patients with hypertension. Thus, the research focused on the new anti-hypertensive treatment is important. Recent SPRINT study clearly identified that lower blood pressure level should be considered to decrease the cardiovascular events. To consider new trend, it is more desirable to develop the more aggressive anti-hypertensive treatments. In this symposium, in order to reconsider more aggresive hypertension treatment, the abstracts related to 1) the preventive medicine, 2) diagnosis and management regarding ICT monitoring, and 3) the innovative treatment strategy related to new anti-hypertensive drugs as well device are welcome. Chairman would like to discuss the future medicine in more aggressive hypertension treatment in this symposium.

(9)Genetic Background of Sudden Cardiac Death

March 18 (Sat) 14:30-16:00

Room6(Hotel Nikko Kanazawa, 3F, Kujaku A)

Chairperson: Minoru Horie(Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science)
Wataru Shimizu(Department of Cardiovascular Medicine, Graduate School of Medicine, Nippon Medical School)
Speaker: Takeshi Aiba(Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center)
Hiroya Matsumura(Department of Cardiology, Hiroshima University Graduate School of Biomedical and Health sciencies)
Keiko Sonoda(Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences)
Mihoko Kawabata(Hert Rhythm Center, Tokyo Medical and Dental University)
Kenshi Hayashi(Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medical Science)
Hitoshi Horigome(Department of Child Health, University of Tsukuba)
Yukiko Hata(Department of Legal Medicine, University of Toyama)
Symposia 〈Japanese〉
(9) Genetic Background of Sudden Cardiac Death
Chairperson: Minoru Horie(Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science)
Wataru Shimizu(Department of Cardiovascular Medicine, Graduate School of Medicine, Nippon Medical School)

Although ischemic heart disease is a leading cause of sudden cardiac death (SCD), inherited cardiac diseases account for constant rate as a cause of SCD. Inherited cardiac diseases consist of cardiac myopathy such as hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and arrhythmogenic right ventricular cardiomyopathy (ARVC), and electrical arrhythmic syndromes such as congenital long QT syndrome (LQTS), Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT), short QT syndrome (SQTS), and more recently early repolarization syndrome (ERS). SCD in inherited cardiac diseases generally occur in young to middle age, therefore, it is important in health policy to prevent SCD and to reveal its pathophysiology. Over the past two decades, molecular genetic studies have established a link between a number of inherited cardiac diseases and mutations in genes encoding for cytoskeletal and desmosomal proteins, ion channels or other membrane components. In some inherited cardiac diseases, genotype-phenotype correlation has been sufficiently investigated, and attributable to risk stratification as well as genotype-specific therapy in individuals. In this symposium, expert physicians and researchers are welcome to present their own experience and provide a comprehensive discussion for the growing cutting-edge of SCD due to inherited cardiac diseases.

(10)Molecular Basis of Cardiovascular Dysfunction in Metabolic Diseases

March 18 (Sat) 14:30-16:00

Room13(Hotel Kanazawa, 2F, Diamond AB)

Chairperson: Tohru Minamino(Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences)
Ajay Chawla(University of California, USA)
Keynote Lecture: Ajay Chawla(University of California, USA)
Speaker: Koji Ohashi(Morecular Cardiovascular Medicine, Nagoya University Graduate School of Medicine)
Koh Ono(Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine)
Yogi Umbarawan(Department of Medicine and Biological Science Gunma University)
Shigeo Godo(Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine)
Tohru Minamino(Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences)
Symposia 〈English〉
(10) Molecular Basis of Cardiovascular Dysfunction in Metabolic Diseases
Chairperson: Tohru Minamino(Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences)
Ajay Chawla(University of California, USA)

It is thought that the mechanisms underlying the development of cardiovascular complications in patients with metabolic diseases, such as diabetes, metabolic syndrome, and dyslipidemia, involve various pathways of cellular and inter-organ communication, but the overall picture remains obscure. For example, the onset of heart failure in patients with diabetes could be attributable to impaired inter-organ communication (cardio-renal, cardio-cerebral, cardio-adipose tissue, and cardio-skeletal muscle communication), as well as to microvascular/macrovascular disease and metabolic abnormalities affecting cardiomyocytes. It has also been shown that cardiovascular dysfunction can exacerbate metabolic diseases by affecting systemic or local (cellular or tissue) metabolic regulatory networks, but the molecular basis of such effects is largely unknown. The previous clinical studies demonstrated that intensive blood glucose lowering treatment with insulin or sulfonylureas could not decrease cardiovascular events. In contrast, the results of a recent clinical study investigating the influence of an SGLT2 inhibitor on cardiovascular outcomes in patients with diabetes had a high impact. The primary action of SGLT2 inhibitors is to promote urinary excretion of glucose, leading to various beneficial effects such as reduction of blood pressure and body weight as well as improvement of insulin resistance and dyslipidemia. These pleiotropic effects of SGLT2 inhibitors can significantly reduce cardiovascular events in diabetic patients. The results of the above-mentioned clinical study indicate that complex mechanisms underlie the induction of cardiovascular dysfunction by metabolic stress. At this symposium, we expect the presentations to highlight a broad range of research that will help to clarify the molecular basis of cardiovascular dysfunction in patients with metabolic diseases.

(11)Cutting Edge Ablation Procedures in Patients with Structural Heart Disease and Sustained Ventricular Tachycardias

March 18 (Sat) 14:30-16:00

Room15(Hotel Kanazawa, 4F, Emerald AB)

Chairperson: Akihiko Nogami(Cardiovascular Division, University of Tsukuba)
Hiroshi Tada(Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui)
Speaker: Yuki Komatsu(Cardiovascular Division, University of Tsukuba)
Masahiko Goya(Heart Rhythm Center, Tokyo Medical and Dental University)
Miyako Igarashi(Cardiovascular Center, Tsuchiura Kyodo General Hospital)
Koji Miyamoto(Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center)
Kazuhiro Satomi(Department of Cardiology, Tokyo Medical University)
Symposia 〈Japanese〉
(11) Cutting Edge Ablation Procedures in Patients with Structural Heart Disease and Sustained Ventricular Tachycardias
Chairperson: Akihiko Nogami(Cardiovascular Division, University of Tsukuba)
Hiroshi Tada(Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui)

With the growing number of patients with implantable devices as well as improvements in heart failure therapy resulting in an improved survival among ICD patients, the overall number of patients needing therapy for ventricular tachycardia (VT) continues to increase. Over the last few decades, catheter ablation has become an important management strategy in reducing the VT burden in patients with structural heart disease (SHD).

With recent advances in our understanding of the arrhythmic substrate in various cardiomyopathies, substrate-based approaches for unmappable VT ablation during sinus rhythm have become possible. Furthermore, the continuous development of better technologies and techniques for VT ablation such as the use of 3-D mapping systems and percutaneous epicardial ablation, innovation of multielectrode catheters for rapid mapping, and the use of intracardiac echocardiography (ICE) for mapping unusual sites, has overcome the limitations and greatly improved the success rates of VT ablation.

In this symposium, eminent physicians in this field will present the cutting edge mapping and ablation approaches and the results and limitations at present for sustained VTs with 5 representative SHDs, such as ischemic cardiomyopathy, dilated cardiomyopathy, hypertrophic cardiomyopathy, cardiac sarcoidosis, and arrhythmogenic right ventricular cardiomyopathy. We plan to have 5 presentations in this session: Each presenter will provide a presentation on one of the 5 etiologies of SHDs.

(12)Understanding the Mechanism of Pulmonary Hypertension

March 18 (Sat) 17:20-18:50

Room13(Hotel Kanazawa, 2F, Diamond AB)

Chairperson: Keiichi Fukuda(Department of Cardiology, Keio University School of Medicine)
Marlene Rabinovitch(Stanford University School of Medicine, USA)
Keynote Lecture: Marlene Rabinovitch(Stanford University School of Medicine, USA)
Speaker: Youyang Zhao(University of Illinois, USA)
Kohtaro Abe(Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University)
Taiju Sato(Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine)
Mitsushige Murata(Department of Cardiology, School of Medicine, Keio University)
Symposia 〈English〉
(12) Understanding the Mechanism of Pulmonary Hypertension
Chairperson: Keiichi Fukuda(Department of Cardiology, Keio University School of Medicine)
Marlene Rabinovitch(Stanford University School of Medicine, USA)

Recently, therapeutic strategies for pulmonary hypertension (PH) have been dramatically advanced. Three types of vasodilators were developed for pulmonary arterial hypertension (PAH), and the prognosis of PAH has been greatly improved by proposal of upfront therapy. However, there are a certain number of patients who are refractory for these 3 types of vasodilators. It has been reported that BMPRII mutations are related with pathogenesis of idiopathic and familial PAH, although these mutations are not found in all cases. There are other possibilities regarding underlying mechanisms of PAH, such as unknown genetic abnormalities, epigenetic regulation, external factors, and environmental factors. In order to improve the prognosis of patients who are refractory for 3 types of vasodilators, detailed underlying mechanisms should be more explored, and the realization of individualized medicine based on underlying mechanisms of each patient would be strongly desired. Furthermore, the underlying mechanisms of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary veno-occlusive disease (PVOD) have yet to be elucidated fully. Catheter-based therapy for CTEPH has been developed mainly in Japan, but the effective therapeutic strategies for PVOD have yet to be developed. In this session, the works to elucidate the underlying mechanisms of PH will be selected, and we would like to discuss futuristic view of therapeutic strategies based on underlying mechanisms of PH.

(13)The Prospective Treatment Strategy for Acute and Chronic Type B Aortic Dissection

March 19 (Sun) 8:30-10:00

Room3(ANA Crowne Plaza Kanazawa, 3F, Ohtori)

Chairperson: Hideaki Yoshino(Department of Cardiology, Kyorin University School of Medicine)
Toru Kuratani(Minimally Invasive Cardiovascular Medicine, Osaka University Graduate School of Medicine)
Speaker: Yasuyuki Tsujita(Shiga University of Medical Science Hospital)
Shuichiro Kaji(Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital)
Kenichi Hagiya(Department of Cardiology, Sakakibara Heart Institute)
Koichi Akutsu(Division of Cardiovascular Intensive Care, Nippon Medical School)
Kazuo Shimamura(Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine)
Hideyuki Shimizu(Department of Cardiovascular Surgery, Keio University)
Symposia 〈Japanese〉
(13) The Prospective Treatment Strategy for Acute and Chronic Type B Aortic Dissection
Chairperson: Hideaki Yoshino(Department of Cardiology, Kyorin University School of Medicine)
Toru Kuratani(Minimally Invasive Cardiovascular Medicine, Osaka University Graduate School of Medicine)

The incidence of type B aortic dissection in Japan is said to be three times higher than in Europe and North America. For this reason, Japanese clinical treatment modalities for this disorder have included endovascular aortic repair (TEVAR) from about 1994, earlier than the rest of the world, in addition to the conventional medical interventions and open repair. Subsequently, a wide range of treatment strategies has been considered and guidelines established within the context of these methods. However, the current situation is that those therapies have not yielded satisfactory long-term results.

In recent years, various modalities have been utilized for the fluid dynamic analysis of aortic dissection, including pressure, flow pattern, and wall share stress. There is much to indicate that treatment strategies for aortic dissection will be completely changed due to these research outcomes.

Therefore, in this session, we will not only have presentations on conventional treatment strategies, but will also learn about those based on research on type B aortic dissection conducted at various hospitals. We will then have a comprehensive discussion to explore and propose new strategies for treating type B aortic dissection in Japan.

(14)Precision Medicine Based on Genetic Information

March 19 (Sun) 8:30-10:00

Room13(Hotel Kanazawa, 2F, Diamond AB)

Chairperson: Issei Komuro(Department of Cardiovascular Medicine, The University of Tokyo)
Sekar Kathiresan(Massachusetts General Hospital, USA)
Keynote Lecture: Sekar Kathiresan(Massachusetts General Hospital, USA)
Speaker: Hayato Tada(Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine)
Toshihiro Tanaka(Bioresource Research Center, Research and Industry-University Alliance Organization Tokyo Medical and Dental University)
Yusuke Ebana(Life Science and Bioethics Research Center, Tokyo Medical and Dental University)
Wataru Shimizu(Department of Cardiovascular Medicine, Graduate School of Medicine, Nippon Medical School)
Seitaro Nomura(Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo)
Symposia 〈English〉
(14) Precision Medicine Based on Genetic Information
Chairperson: Issei Komuro(Department of Cardiovascular Medicine, The University of Tokyo)
Sekar Kathiresan(Massachusetts General Hospital, USA)

Precision Medicine Based on Genetic Information Precision medicine can be defined as treatments targeted to the needs of individual patients on the basis of clinical characteristics (e.g. genetic marker) that distinguish a given patient from other patients with similar clinical presentations, enabling us to improve clinical outcomes and maximize therapeutic responses for individual patients. Genomewide association studies have uncovered many common genetic loci or variations associated with common cardiovascular diseases such as coronary artery disease, aortic-valve calcification, and atrial fibrillation. Although these common disease-associated loci or variations could provide with us the mechanistic insight into the pathophysiology as well as the possible therapeutic targets, they have been seldom applied to risk prediction in a clinical setting. Further efforts should be made for purpose of realizing precision medicine as to the common diseases. On the other hand, as for the monogenic inherited diseases such as cardiomyopathy and Long QT syndrome, knowing mutation-specific consequences can be useful for predicting the difference in a patient’s clinical features and prognosis, leading to the appropriate risk stratification. For example, the presence of a mutation linked to sudden cardiac death could justify consideration of a prophylactic implantable cardioverter defibrillator implant. In this symposium, we summarize the implication of updated genomic data in the cardiovascular area for clinical practice, providing the prospects on the upcoming genomic research required for the realization of precision medicine.

(15)Novel Approaches for Cardiac Arrhythmias
(※Partly in English)

March 19 (Sun) 11:10-12:40

Room3(ANA Crowne Plaza Kanazawa, 3F, Ohtori)

Chairperson: Teiichi Yamane(Jikei University School of Medicine)
Nobuhisa Hagiwara(Department of Cardiology, Tokyo Women's Medical University)
Keynote Lecture: Shih-Ann Chen(National Yang Ming University / Taipai Veteran General Hospital, Taiwan)
Speaker: Takeshi Tsuchiya(EP Expert Doctors-Team Tsuchiya)
Seigo Yamashita(Hopital Cardiologique du Haut-Leveque, CHV de Bordeaux, France)
Kunihiko Kiuchi(Section of Arrhythmia, Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University)
Atsushi Suzuki(Department of Cardiology, Tokyo Women's Medical University)
Hitoshi Minamiguchi(Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine)
Symposia 〈Japanese(Partly in English)〉
(15) Novel Approaches for Cardiac Arrhythmias
Chairperson: Teiichi Yamane(Jikei University School of Medicine)
Nobuhisa Hagiwara(Department of Cardiology, Tokyo Women's Medical University)

Among various fields in the Cardiology, there have been remarkable advances in approaches/therapies for cardiac arrhythmias recently. The biggest progression will be in the management of "Fibrillation". Both atrial and ventricular (not all, but some of ) fibrillation, which had been incurable diseases until 21st century, has become the target of catheter ablation. Furthermore, in addition to the traditional radiofrequency-energy, cryothermy coagulation and laser-energy have become the choices for catheter ablation. As for the targets of ablation energy, drivers/rotors which are essential for the perpetuation of atrial fibrillation has been focused along with the progression of 3D technologies. In the field of implantable devices, developments in ICT has enabled the "Remote Monitoring" which can improve the patient prognosis by early intervention of incidences. On the other hand of these recent advancements, we should be aware the limitations in our managements of arrhythmias, for the further progressions. In this symposium, we would like to discuss both the utility and limitation of new approaches for cardiac arrhythmias.

(16)Requirement of Novel Intervention to Residual Risk in Patients with Coronary Artery Disease

March 19 (Sun) 11:10-12:40

Room8(Porte Kanazawa, 6F, Kanazawa Art Hall)

Chairperson: Shinichiro Ueda(Department of Clinical Pharmacology and Therapeutics, University of the Ryukyus School of Medicine)
Masataka Sata(Department of Cardiovascular Medicine, Tokushima University Hospital)
Speaker: Shinichiro Ueda(Department of Clinical Pharmacology and Therapeutics, University of the Ryukyus School of Medicine)
Takuya Nakahashi(Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine)
Shusuke Yagi(Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences)
Tomoya Yamashita(Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine)
Daisaku Masuda(Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine)
Mitsuaki Sawano(Department of Cardiology, Keio University School of Medicine)
Symposia 〈Japanese〉
(16) Requirement of Novel Intervention to Residual Risk in Patients with Coronary Artery Disease
Chairperson: Shinichiro Ueda(Department of Clinical Pharmacology and Therapeutics, University of the Ryukyus School of Medicine)
Masataka Sata(Department of Cardiovascular Medicine, Tokushima University Hospital)

In addition to control of traditional risk factors, use of statin, ACE inhibitor, beta blocker and aspirin has been recommended as standardized medical therapy for patients with coronary artery disease(CAD). Such strategy, however, is considered not fully efficient because there remains high residual risk particularly in diabetic CAD patients under the standardized treatment, Clinical trials reflecting current CAD treatment as well as exploratory studies for the development of newer drugs and biomarkers are apparently needed. in this symposium, we are keen on reviewing recent advance in results from clinical epidemiology, clinical trials and translations research and discussing newer intervention contributing to reduction in residual risk.

(17)Heart Failure and Diabetes Mellitus

March 19 (Sun) 11:10-12:40

Room10(Kanazawa Miyako Hotel, 5F, Kaga)

Chairperson: Koichi Node(Department of Cardiovascular Medicine, Saga University)
Ulrich Laufs(Saarland University, Germany)
Keynote Lecture: Ulrich Laufs(Saarland University, Germany)
Speaker: Atsushi Tanaka(Department of Cardiovascular Medicine, Saga University)
Ippei Shimizu(Department of Cardiovascular Biology and Medicine, Niigata University)
Motoaki Sano(Department of Cardiology, Keio University School of Medicine)
Kazuo Eguchi(Division of Cardiovascular Medicine, Jichi Medical University School of Medicine)
Yasuko Bando(Department of Cardiology, Nagoya University Graduate School of Medicine)
Hirotsugu Yamada(Department of Cardiovascular Medicine, Tokushima University Hospital)
Symposia 〈English〉
(17) Heart Failure and Diabetes Mellitus
Chairperson: Koichi Node(Department of Cardiovascular Medicine, Saga University)
Ulrich Laufs(Saarland University, Germany)

In Framingham heart study, the risk for heart failure is 6 times higher for male, and 10 times for females with diabetes mellitus, and glucose intolerance associates with the onset or exacerbation of diastolic heart failure. It is possible that hyperglycemia causes cardiomyocyte hypertrophy and cardiac fibrosis, cardiac subendocardial ischemia with vascular endothelial dysfunction and microcirculatory disturbance, cardiac toxicity induced by fatty acid with insulin resistance, mitochondrial dysfunction with ATP depletion. The mechanism of heart failure induced by diabetes mellitus remains unknown.

On the other hand, pioglitazone for heart failure and metformin for severe cardiac dysfunction is contraindicated. Saxagliptin, the DPP4 inhibitor, increased the number of heart failure hospitalization in SAVOR study, but sitagliptin showed no adverse effect for heart failure in TECOS study, suggesting that the contribution of incretin derivative for heat failure remains unrevealed. SGLT2 inhibitors might reduce the onset of heart failure by its’ diuretic and antihypertensive effect, since empagliflozin reduced the heart failure mortality and hospitalization in EMPA-REG OUTCOME study.

There are no much of evidence to index the proper control level of HbA1c, or prescribe the appropriate medicine. In this symposium, we expect to see the newest data that shows the relationship with diabetes mellitus and heart failure from basic and clinical setting, and believe that will contribute to the advancement of heart failure prevention in patients with diabetes mellitus.

(18)Heart Team –Current Issues and Future Perspective–

March 19 (Sun) 14:00-15:30

Room16(Hotel Kanazawa, 5F, Party Room)

Chairperson: Takashi Akasaka(Department of Cardiovascular Medicine, Wakayama Medical University)
Junya Ako(Department of Cardiovascular Medicine, Kitasato University School of Medicine)
Speaker: Shun Kohsaka(Department of Cardiology, Keio University School of Medicine)
Kei Torikai(Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine)
Masahiro Yamawaki(Cardiovascular Center, Saiseikai Yokohama City Eastern Hospital)
Noriko Kikuchi(Department of Cardiology, Tokyo Women's Medical University)
Masahiko Gohya(Department of Cardiovascular Medicine, Tokyo Medical and Dental University)
Symposia 〈Japanese〉
(18) Heart Team –Current Issues and Future Perspective–
Chairperson: Takashi Akasaka(Department of Cardiovascular Medicine, Wakayama Medical University)
Junya Ako(Department of Cardiovascular Medicine, Kitasato University School of Medicine)

Recently the importance of “heart team” has been stressed in clinical cardiology. Heart team, consisted of cardiologists, cardiac surgeons, anesthesiologists, and a number of co-medical personnels, makes the decisions on patients’ therapeutic options and even performs treatments as a team. Heart team is considered important in decision making in ischemic heart disease such as left main disease or multiple vessel disease. Heart team is also a requirement for TAVI (transcatheter aortic valve implantation), which is currently performed in an increasing number of facilities. European Society of Cardiology strongly supports the concept of Heart team, which is now included in the current ESC guidelines.

Heart team is conceptually an excellent idea. However, does it really work as initially planned? Aren’t there any issues in creating and executing Heart team? In this session, current issues and future perspectives regarding Heart team will be presented and discussed.

(19)Issues to be Solved to Improve Survival Rate and Quality of Life in Patients with Heart Transplanation

March 19 (Sun) 16:40-18:10

Room2(Ishikawa Ongakudo, 2F, Hogaku Hall)

Chairperson: Minoru Ono(Department of Cardiac Surgery, Graduate School of Medicine, The University of Tokyo)
Yasushi Sakata(Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine)
Speaker: Noboru Oda(Department of Cardiology, Hiroshima City Asa Hospital)
Tatsuo Aoki(Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine)
Yasushi Yoshikawa(Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine)
Masanobu Yanase(Division of Transplantation, National Cerebral and Cardiovascular Center)
Hatsue Ueda(Department of Pathology, National Cerebral and Cardiovascular Center)
Yasumasa Tsukamoto(Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine)
Eisuke Amiya(Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo)
Symposia 〈Japanese〉
(19) Issues to be Solved to Improve Survival Rate and Quality of Life in Patients with Heart Transplanation
Chairperson: Minoru Ono(Department of Cardiac Surgery, Graduate School of Medicine, The University of Tokyo)
Yasushi Sakata(Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine)

Heart transplantation is the best treatment to improve the survival rate and the quality of life in the patients with Stage-D heart failure. It has been 17 years since heart transplantation restarted in Japan. The survival rate of the patients undergoing heart transplantation in Japan is better than that of those in the world. However, the number of donor's hearts here is much smaller than in the other countries, resulting in long-time waiting of the candidates, and unwanted treatment using marginal donor hearts. Therefore, it is important to maintain the nominees’ condition before transplantation. Also, there are still many issues to be solved after transplantation such as rejection, infection, malignancy. In this symposium, we would like to discuss how to improve the survival rate and quality of life in the patients before and after heart transplantation.

(20)Reconsidering the Progress of Emergency Cardiovascular Care and Reconstructing the Future of This Field with New Concept and Technology Development

March 19 (Sun) 16:40-18:10

Room5(Hotel Nikko Kanazawa, 3F, Kujaku BC)

Chairperson: Morimasa Takayama(Sakakibara Heart Institute)
Shunichi Miyazaki(Saiseikai-Tondabayashi Hospital)
Speaker: Yasushi Ueki(Shinshu University School of Medicine Emergency and Critical Care Center)
Shoji Kawakami(Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center)
Kenji Inoue(Department of Cardiology, Juntendo University Nerima Hospital)
Jun Nakata(Schwabing Hospital, Germany)
Hideto Sangen(Division of Cardiovascular Intensive Care, Nippon Medical School Hospital)
Takahiro Okumura(Department of Cardiology, Nagoya University Graduate School of Medicine)
Symposia 〈Japanese〉
(20) Reconsidering the Progress of Emergency Cardiovascular Care and Reconstructing the Future of This Field with New Concept and Technology Development
Chairperson: Yasushi Ueki(Shinshu University Hospital Critical Care Center)
Shoji Kawakami(Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center)

Since 1960’s, we have a lot of progress in the field of cardiovascular emergency medicine, such as introduction of CCU for fatal arrhythmia and DC defibrillation in 1970’s, then afterload reduction therapy including IABP, Swan-Ganz catheter for the bed side hemodynamic monitoring, coronary thrombolysis in 1980’s, and finally the concept of ACS and primary PCI for AMI, PCPS for critically damaged heart in 1990’s to early 2000’s. On the other hand, we might focus on the technique of PCI too much, resulting in underestimate the importance of basic understanding for hemodynamics, of intensive care medicine for cardiovascular patients such as shock treatment, infection control, respiratory condition and of taking care for mental state. Therefore, we plan to make the real world of modern cardiovascular emergency clarified and to recognize the role of cardiologist and emergent physician in the field of cardiovascular emergency and intensive care medicine.

Joint Symposia

(1)ACC-JCS Joint Symposium
Recent Progress in Catheter Ablation for Atrial Fibrillation

March 17 (Fri) 8:50-10:20

Room2(Ishikawa Ongakudo, 2F, Hogaku Hall)

Chairperson: Ken Okumura(Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center)
Hugh Calkins(John's Hopkins Hospital, USA)
Speaker: Masaomi Kimura(Department of Hypertension Stroke Medicine, Hirosaki University Graduate School of Medicine)
Shinsuke Miyazaki(Cardiovascular Center, Tsuchiura Kyodo Hospital)
Atul Verma(University of Toronto, Canada)
Hugh Calkins(John's Hopkins Hospital, USA)
Joint Symposia
(1) ACC-JCS Joint Symposium
Recent Progress in Catheter Ablation for Atrial Fibrillation
Chairperson: Ken Okumura(Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center)
Hugh Calkins(John's Hopkins Hospital, USA)

Catheter ablation is now a standard-of-care procedure for drug-refractory atrial fibrillation (AF). This is largely due to a number of previous clinical investigations that have been challenging to establish more effective strategies and progress in the technologies that support the ablation procedures. Technological progress include 3D-mapping and catheter navigation system, contact force-sensing catheter, and various modules for evaluating the electrogram characteristics possibly related to the pathogenesis of AF and the lesions ablated. As an alternative to radiofrequency ablation, cryoballoon ablation system has been available and now is widely used for pulmonary vein isolation in paroxysmal AF patients. With these advances, the outcome after ablation for paroxysmal AF has been much improved. However, that for persistent AF, especially for long-standing persistent AF, remains to be challenged. In this ACC-JCS Joint Symposium, recent progress in AF ablation will be presented and the unmet needs in AF ablation to be addressed will be discussed.

(2)AHA-JCS Joint Symposium
Current Status of Antiplatelet Therapy

March 19 (Sun) 14:00-15:30

Room4(Visage Building, 11F, Visage Conference Room1)

Chairperson: Shinya Goto(Institute of Medical Sciences, Tokai University)
Peter Libby(Harvard Medical School, USA)
Speaker: Peter Libby(Harvard Medical School, USA)
Kengo Ayabe(Department of Cardiology, Tokai University School of Medicine)
Shu Takagi(The Department of Mechanical Engineering, The Tokyo University Graduate School of Engineering)
Hisanori Horiuchi(Institute of Development, Aging and Cancer, Tohoku University)
Mary Cushman(University of Vermont, USA)
Joint Symposia
(2) AHA-JCS Joint Symposium
Current Status of Antiplatelet Therapy
Chairperson: Shinya Goto(Institute of Medical Sciences, Tokai University)
Peter Libby(Harvard Medical School, USA)

Anti platelet therapy is one of the most common treatment strategy in patients care in Cardiology. It prevent thrombotic events such as myocardial infarction, but increase the risk for serious bleeding. With the accumulated clinical evidence, there are some population of patients who get benefit more than harm, in the other patient population get harm than benefit. The absolute benefit and harm depend on the thrombotic risk of patient population. In general, thrombotic events are low in East Asian countries such as Japan as compared to Western countries including the US. Indeed, some of antiplatelet agents such as prasugrel  was approved in the different dose in Japan as compared to the other regions of the world (only 1/3 dose in Japan). It is rather difficult to develop evidence based guideline in the world with different thrombotic and bleeding risk. In this section, we will discuss about current status of antiplatelet therapy in Japan and the US. 

(3)CSC-JCS Joint Symposium
HFPEF and Diastolic Dysfunction

March 18 (Sat) 11:10-12:40

Room3(ANA Crowne Plaza Kanazawa, 3F, Ohtori)

Chairperson: Kazuhiro Yamamoto(Department of Molecular Medicine and Therapeutics, Tottori University)
Yunzeng Zou(Zhongshan Hospital, Fudan University, China)
Speaker: Masaaki Takeuchi(Department of Laboratory and Transfusion Medicine, University of Occupational and Environmental Health, School of Medicine)
Jingmin Zhou(Zhongshan Hospital Fudan University, China)
Yoshihiro Seo(Cardiovascular Division, University of Tsukuba)
Jian Zhang(Fu Wai Hospital, China)
Joint Symposia
(3) CSC-JCS Joint Symposium
HFPEF and Diastolic Dysfunction
Chairperson: Kazuhiro Yamamoto(Department of Molecular Medicine and Therapeutics, Tottori University)
Yunzeng Zou(Zhongshan Hospital, Fudan University, China)

Heart failure incidence rises with age, and the number of patients with heart failure is cumulatively increased. In elder patients with heart failure, the prevalence of HFPEF is predominant as compared with HFREF. HFPEF is considered to develop on the basis of LV diastolic dysfunction. However, the detection of LV diastolic dysfunction in subjects with preserved EF is not easy, and thus, clinical characteristics of HFPEF has not been fully understood. Furthermore, the previous clinical trials have failed to demonstrate effective therapeutic strategies for HFPEF. In this session, we would like to share the current knowledge about HFPEF and diastolic dysfunction with experts in China and Japan.

(4)Asian Session
Vascular Failure : From Bench to Bedside

March 18 (Sat) 8:30-10:00

Room13(Hotel Kanazawa, 2F, Diamond AB)

Chairperson: Koji Maemura(Department of Cardiovascular Medicine, Nagasaki University)
Hung-I Yeh(Mackay Memorial Hospital, Taiwan)
Speaker: Hirofumi Tomiyama(Department of Cardiology, Tokyo Medical University)
Hyun-Jai Cho(Seoul National University Hospital, Korea)
Po-Hsun Huang(Taipei Veterans General Hospital, Taiwan)
Kenny Yoong Kong(National Heart Centre Singapore, Singapore)
Joint Symposia
(4) Asian Session
Vascular Failure : From Bench to Bedside
Chairperson: Koji Maemura(Department of Cardiovascular Medicine, Nagasaki University)
Hung-I Yeh(Mackay Memorial Hospital, Taiwan)

Cardiovascular diseases are the leading cause of mortality in the world including Asian countries. One of the main causes of cardiovascular diseases is a vascular disorder such as atherosclerosis or arteriosclerosis. These vascular diseases are triggered by multifactorial vascular injury leading to vascular endothelial dysfunction. The dysfunction of vasculature including vascular endothelial cells, smooth muscle cells and surrounding cells has been recently proposed as ‘vascular failure’. Thus, it is critically important for the prevention of cardiovascular diseases to understand the mechanisms of vascular failure and to establish the method to evaluate it clinically. In this session, we would like to discuss the current state of understanding the mechanism of vascular dysfunction and the method of measuring it in the Asian countries.

(5)ESC-JCS Joint Symposium
Recent Advances in Coronary Imaging and Intervention

March 18 (Sat) 17:20-18:50

Room3(ANA Crowne Plaza Kanazawa, 3F, Ohtori)

Chairperson: Yukio Ozaki(Department of Cardiology, Fujita Health University)
Fausto Pinto(University of Lisbon, Portugal)
Speaker: Fausto Pinto(University of Lisbon, Portugal)
Atsushi Tanaka(Department of Cardiovascular Medicine, Wakayama Medical University)
Masato Nakamura(Toho University Ohashi Medical Center)
Marco Roffi(Geneva University Hospital, Switzerland)
Joint Symposia
(5) ESC-JCS Joint Symposium
Recent Advances in Coronary Imaging and Intervention
Chairperson: Yukio Ozaki(Department of Cardiology, Fujita Health University)
Fausto Pinto(University of Lisbon, Portugal)

While atherosclerotic plaques associated with ACS on histopathological characterization demonstrate either ruptured fibrous caps (RFC-ACS) or intact fibrous caps (IFC-ACS), the latter lesions are often referred to as plaque erosions and are responsible for up to one-third of culprit lesions in ACS patients. Whilst IVUS and OCT have significantly contributed to disclose the mechanism of ACS and PCI, various imaging modalities have entered clinical arena. While new ESC guidelines for the management of NSTE ACS was presented at the last ESC congress in London, similar approach has been carried out in STEMI case in Japan consisting of 1) first medical contact to ECG soon as possible (e.g. <10 minutes), 2) primary PCI: ≤90 minutes, 3) stenting is recommended, 4) routine thrombus aspiration should be considered. This session would contribute to “recent advances in coronary imaging and intervention” in both Europe and Japan.

(6)KSC-JCS Joint Symposium
Surgical Treatment for End-stage Heart Failure

March 17 (Fri) 11:30-13:00

Room3(ANA Crowne Plaza Kanazawa, 3F, Ohtori)

Chairperson: Yoshiki Sawa(Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine)
Byung Chul Chang(Yonsei University College of Medicine, Korea)
Speaker: Byung Chul Chang(Yonsei University College of Medicine, Korea)
Jae Won Lee(Asan Medical Center, Korea)
Ki-Bong Kim(Seoul National University Hospital, Korea)
Hitoshi Yokoyama(Department of Cardiovascular Surgery, Fukushima Medical College)
Hitoshi Yaku(Department of Cardiovascular Surgery, Kyoto Prefectural University of Medicine )
Yoshiki Sawa(Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine)
Joint Symposia
(6) KSC-JCS Joint Symposium
Surgical Treatment for End-stage Heart Failure
Chairperson: Yoshiki Sawa(Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine)
Byung Chul Chang(Yonsei University College of Medicine, Korea)

However cardiovascular surgery have been developed for life saving surgery, current advances such as minimally invasive cardiac surgery including off pump bypass enable higher levels of QOL for patients. More recently, hybrid operation such as TEVAR, EVAR and TAVI are promising less invasive cardiovascular surgery. On the other hand, heart failure surgery is increasing its importance while the westernization of Asian lifestyle are in association with the growth of aging society. In these backgrounds, cardiovascular surgeon need to adapt the new surgical technologies and promote more educational strategy for younger surgeon in new era of changing cardiovascular surgery. Korea and Japan are the neighborhood countries and have similar goal and problems as the same Asian countries. Therefore, both countries should collaborate each other in surgical strategies, clinical studies and educational programs. In this symposium, we would like to discuss our current surgical topics and how to collaborate each other for better our future.

(7)Meet the ESC in Japan Session1
Recent Advances in the Management of Aortic Diseases

March 18 (Sat) 8:30-10:00

Room3(ANA Crowne Plaza Kanazawa, 3F, Ohtori)

Chairperson: Toyoaki Murohara(Department of Cardiology, Nagoya University Graduate School of Medicine)
Jeroen Bax(Leiden University Medical Center, The Netherlands)
Speaker: Stephan Achenbach(University of Erlangen, Germany)
Kazuhiro Nishigami(Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center)
Marco Roffi(Geneva University Hospital, Switzerland)
Mitsuaki Isobe(Department of Cardiovascular Medicine, Tokyo Medical and Dental University)
(8)Meet the ESC in Japan Session2
Registries and Innovation in Research

March 18 (Sat) 14:30-16:00

Room3(ANA Crowne Plaza Kanazawa, 3F, Ohtori)

Chairperson: Hiroyuki Tsutsui(Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Science)
Genevieve Derumeaux(Hopital Henri Mondor, France)
Speaker: Alec Vahanian(Hospital Bichat, France)
Takeshi Kimura(Kyoto University Hospital Cardiovascular Medicine)
Michel Komajda(University Pierre and Marie Curie Pitie / Slapetriere Hospital, France)
Masaharu Akao(National Hospital Organization Kyoto Medical Center)

Round Table Discussion

(1)

March 17 (Fri) 11:30-13:00

Room5(Hotel Nikko Kanazawa, 3F, Kujaku BC)

Chairperson: Kengo Kusano(Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center)
Takanori Ikeda(Department of Cardiovascular Medicine, Toho University Faculty of Medicine)
Speaker: Hiroshi Morita(Department of Cardiovascular Therapeutics, Okayama University Graduate School of Medicine)
Yukiko Nakano(Department of Cardiovascular Medicine, Hiroshima University)
Yoshiyasu Aizawa(Department of Cardiology, Keio University School of Medicine)
Tsukasa Kamakura(Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center)
Masahiko Takagi(Osaka City University Graduate School of Medicine)
Yasuya Inden(Department of Cardiology, Nagoya University Graduate School of Medicine)
(2)

March 17 (Fri) 17:00-18:30

Room3(ANA Crowne Plaza Kanazawa, 3F, Ohtori)

Chairperson: Masaaki Ito(Department of Cardiology and Nephrology, Mie University Graduate School of Medicine)
Hiroshi Imamura(Department of Emergency and Critical Care Medicine, Shinshu University School of Medicine)
Speaker: Yoshikazu Goto(Department of Emergency and Critical Care Medicine, Kanazawa University Hospital)
Jun Masuda(Department of Cardiology and Nephrology, Mie University Graduate School of Medicine)
Migaku Kikuchi(Department of Cardiovascular Medicine, Dokkyo Medical University)
Osahiko Sunagawa(Department of Cardiology, Okinawa Prefectural Nanbu Medical Center and Children's Medical Center)
Hiroshi Imamura(Department of Emergency and Critical Care Medicine, Shinshu University School of Medicine)
(3)

March 18 (Sat) 11:10-12:40

Room9(Kanazawa Miyako Hotel, B2F, Seminar Hall)

Chairperson: Kentaro Hayashida(Department of Cardiology, Keio University School of Medicine)
Hitoshi Yaku(Department of Cardiovascular Surgery, Kyoto Prefectural University of Medicine)
Speaker: Mitsushige Murata(Department of Cardiology, Keio University School of Medicine)
Yutaka Koyama(Department of Cardiovascular Surgery, Nagoya Heart Center)
Shinichi Shirai(Department of Cardiology, Kokura Memorial Hospital)
Yusuke Watanabe(Teikyo University School of Medicine)
Takashi Matsumoto(Sendai Kousei Hospital)
(4)

March 18 (Sat) 11:10-12:40

Room15(Hotel Kanazawa, 4F, Emerald AB)

Chairperson: Kenji Yamazaki(Cardiolovascular Surgery, Tokyo Women's Medical University)
Toshihisa Anzai(Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center)
Speaker: Makoto Amaki(National Cerebral and Cardiovascular Center)
Kenji Ando(Kokura Memorial Hospital)
Kenji Yamazaki(Cardiolovascular Surgery, Tokyo Women's Medical University)
Shigeru Miyagawa(Department of Cardiovascular Surgery, Osaka University)
Masaki Ieda(Department of Cardiology, Keio University School of Medicine)
(5)Sleep Disordered Breathing in Heart Failure: To Treat or Not to Treat?

March 18 (Sat) 17:20-18:50

Room9(Kanazawa Miyako Hotel, B2F, Seminar Hall)

Chairperson: John S. Floras(University of Toronto, Canada)
Shin-ichi Ando(Kyushu University Hospital, Sleep Apnea Center)
State-of-the Art: John S. Floras(University of Toronto, Canada)
Speaker: Hisayoshi Murai(Department of System Biology, Kanazawa University Graduate School of Advanced Preventive Medical Science)
Masayoshi Yoshida(Faculty of Engineering, School of Electrical Engineering and Computer Science, University of Ottawa, USA)
Takatoshi Kasai(Department of Cardiovascular Medicine, Juntendo University)
(6)How to Enhance the Translational Research

March 19 (Sun) 8:30-10:00

Room14(Hotel Kanazawa, 2F, Diamond C)

Chairperson: Moo Hyun Kim(Dong-A University Hospital, Korea)
Toshinori Murayama(Department of Clinical Development, Kanazawa University Hospital)
Speaker: Junichi Sadoshima(Rutgers New Jersey Medical School, USA)
Soon Jun Hong(Korea Univesity Anam Hospital, Korea)
Yuji Shiba(Department of Cardiovascular Medicine, Shinshu University)
Shoji Sanada(Department of Medical Innovation, Osaka University Hospital)
(7)

March 19 (Sun) 16:40-18:10

Room13(Hotel Kanazawa, 2F, Diamond AB)

Chairperson: Hisanori Horiuchi(Institute of Development, Aging and Cancer, Tohoku University)
Yukihiro Koretsune(National Hospital Organization Osaka National Hospital)
Speaker: Yukihiro Koretsune(National Hospital Organization Osaka National Hospital)
Kenji Ando(Kokura Memorial Hospital)
Tsuyoshi Shiga(Department of Cardiolgy, Tokyo Women's Medical University)
Masato Eto(Department of Education and Staff Development, University of Tokyo Hospital)
Hisanori Horiuchi(Institute of Development, Aging and Cancer, Tohoku University)
Hidesaku Asakura(Department of Internal Medicine (III), Kanazawa University School of Medicine)

Topic

(1)Management of Cardiovascular Manifestations in Various Systematic Inflammatory Diseases
(※Partly in English)

March 17 (Fri) 17:00-18:30

Room5(Hotel Nikko Kanazawa, 3F, Kujaku BC)

Chairperson: Nobukazu Ishizaka(Department of Cardiology, Osaka Medical College)
Kyoko Imanaka(Department of Pathology and Matrix Biology, Mie University Graduate School of Medicine)
Speaker: Talia H. Swartz(Icahn School of Medicine at Mount Sinai, USA)
Yoshikazu Yazaki(Division of Cardiovascular Medicine, Saku Central Hospital Advanced Care Center)
Etsuko Tsuda(National Cerebral and Cardiovascular Center)
Ichiro Mizushima(Department of Cardiovascular and Internal Medicine, Kanazawa University Hospital)
Yoshihiro Fukumoto(Division of Cardiovascular Medicine, Kurume University School of Medicine)
Kazuko Tajiri(Division of Cardiovascular, University of Tsukuba)
(2)

March 18 (Sat) 8:30-10:00

Room1(Ishikawa Ongakudo, 2F, Concert Hall)

Chairperson: Naomasa Makita(Department of Molecular Physiology, Nagasaki University)
Naohiko Takahashi(Department of Cardiovascular Science, Oita University)
Speaker: Tetsushi Furukawa(Department of Bio-informational Pharmacology, Medical Research Institute, Tokyo Medical and Dental University)
Taisuke Ishikawa(Department of Molecular Physiology, Nagasaki University Graduate School of Biomedical Sciences)
Takeshi Kato(System Biology, Kanazawa University Graduate School of Advanced Preventive Medical Sciences)
Ichitaro Abe(Department of Cardiology and Clinical Examination, Oita University)
Yoshihiro Kokubo(Department of Preventive Cardiology, National Cerebral and Cardiovascular Center)
(3)Endothelium, Health and Diseases

March 18 (Sat) 11:10-12:40

Room12(Kanazawa Miyako Hotel, 7F, Hishoh)

Chairperson: Yoh Takuwa(Department of Physiology, Kanazawa University School of Medicine)
Alan Daugherty(University of Kentucky, USA)
Speaker: Alan Daugherty(Saha Cardiovascular Research Center, University of Kentucky, USA)
Kazuaki Yoshioka(Department of Physiology, Kanazawa University School of Medicine)
Yuichi Hattori(Department of Molecular and Medical Pharmacology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama)
Tatsuya Sawamura(Institute of Medicine, Shinsyu University)
Yu Huang(Chinese University of Hong Kong, Hong Kong)
Takeshi Tokudome(Department of Biochemistry, National Cerebral and Cardiovascular Center Research Institute)
(4)

March 18 (Sat) 17:20-18:50

Room16(Hotel Kanazawa, 5F, Party Room)

Chairperson: Tetsuji Miura(Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University)
Hiroshi Akazawa(Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo)
Speaker: Ippei Shimizu(Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences)
Satoaki Matoba(Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine)
Masaya Tanno(Dapartment of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine)
Makoto Kuro-o(Division of Anti-aging Medicine, Center for Molecular Medicine, Jichi Medical University)
Atsuhiko Naito(Department of Pharmacology, Toho University)
(5)Future Trend of Molecular Imaging in Cardiovascular Medicine: From Basic to Clinical Aspects

March 19 (Sun) 11:10-12:40

Room5(Hotel Nikko Kanazawa, 3F, Kujaku BC)

Chairperson: Kenichi Nakajima(Nuclear Medicine, Kanazawa University)
Hideharu Hayashi(Third Department of Internal Medicine, Hamamatsu University School of Medicine)
Keynote Lecture: Takahiro Higuchi(University of Würzburg, Germany)
Speaker: Kenji Kabashima(Department of Dermatology, Kyoto University Graduate School of Medicine)
Mitsutoshi Setou(Department of Cell Biology and Anatomy, Hamamatsu University School of Medicine)
Toshio Ando(Science & Engineering, Kanazawa University)
Teruo Noguchi(National Cerebral and Cardiovascular Center)
(6)

March 19 (Sun) 11:10-12:40

Room6(Hotel Nikko Kanazawa, 3F, Kujaku A)

Chairperson: Masahito Yamada(Department of Neuology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences)
Hidenori Arai(National Center for Geriatrics and Gerontology)
Speaker: Toshiharu Ninomiya(Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyusyu University)
Tomoko Tomioka(Southmiyagi Medical Center)
Kenji Sakai(Department of Neurology, Kanazawa University Hospital)
Kazuomi Kario(Division of Cardiovascular Medicine, Jichi Medical University)
Atsuya Shimizu(National Center for Geriatrics and Gerontology)
(7)New Aspects of HFpEF: From Molecular Basis to Treatment

March 19 (Sun) 14:00-15:30

Room15(Hotel Kanazawa, 4F, Emerald AB)

Chairperson: Masafumi Yano(Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine)
Yasuchika Takeishi(Department of Cardiovascular Medicine, Fukushima Medical University)
Speaker: Junichi Sadoshima(Rutgers New Jersey Medical School, USA)
Tetsuro Shishido(Yamagata University Graduate School of Medicine)
Shintaro Kinugawa(Department of Cardiovascular Medicine, Hokkaido University)
Mitsuhiko Yamada(Department of Molecular Pharmacology, Shinshu University School of Medicine)
Shigeki Kobayashi(Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine)
(8)

March 19 (Sun) 16:40-18:10

Room11(Kanazawa Miyako Hotel, 7F, Hoh-Oh)

Chairperson: Ken Kozuma(Division of Cardiolgy, Teikyo University Hospital)
Yutaka Okita(Division of Cardiovascular Surgery, Department of Surgery, Kobe University)
Speaker: Makoto Amaki(National Cerebral and Cardiovascular Center)
Takashi Matsumoto(Sendai Kousei Hospital)
Hikaru Tsuruta(Department of Cardiology, Keio University School of Medicine)
Panelists: Makoto Amaki(National Cerebral and Cardiovascular Center)
Takashi Matsumoto(Sendai Kousei Hospital)
Kentaro Hayashida(Department of Cardiology, Keio University School of Medicine)
Hikaru Tsuruta(Department of Cardiology, Keio University School of Medicine)
Junichi Yamaguchi(Tokyo Women's Medical University)
Tetsuya Tobaru(Sakakibara Heart Institute)
Shingo Mizuno(Shonan Kamakura General Hospital)
Kazuhiro Yamamoto(Department of Molecular Medicine and Therapeutics, Tottori University)

Controversy

(1)

March 17 (Fri) 8:50-10:20

Room8(Porte Kanazawa, 6F, Kanazawa Art Hall)

Chairperson: Naoki Yahagi(Department of Emergency Medicine, The University of Tokyo)
Hiroshi Nonogi(Shizuoka General Hospital)
Speaker: Akira Funada(Department of Emergency and Critical Care Medicine, Kanazawa University Hospital)
Yuichi Hamabe(Tokyo Metropolitan Bokutoh Hospital, Tertiary Emergency Medical Center (Trauma and Critical Care))
Masako Minooka(The University of Tokyo/Minooka Clinic)
Taketoshi Ozawa(Megumi Zaitaku Clinic)
Toshiro Inaba(Department of Cardiovascular Medicine, The University of Tokyo)
(2)

March 17 (Fri) 14:20-15:50

Room13(Hotel Kanazawa, 2F, Diamond AB)

Chairperson: Masaru Sugimachi(Department of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center)
Koji Maemura(Department of Cardiovascular Medicine, Nagasaki University)
Speaker: Yoshio Yasumura(Osaka Police Hospital)
Naoki Sato(Cardiology and Intensive Care Unit, Nippon Medical School Musashi-Kosugi Hospital)
Takeshi Yamashita(The Cardiovascular Institute)
Kazunori Uemura(Department of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center)
(3)

March 17 (Fri) 14:20-15:50

Room15(Hotel Kanazawa, 4F, Emerald AB)

Chairperson: Tohru Asai(Division of Cardiovascular Surgery, Shiga University of Medical Science)
Yoshihiro Morino(Division of Cardiology, Iwate Medical University)
Speaker: Hideki Ishii(Department of Cardiology, Nagoya University Graduate School of Medicine)
Takuya Nakahashi(Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine)
Toshihiro Fukui(Department of Cardiovascular Surgery, Kumamoto University Hospital)
Hiroyuki Nakajima(Saitama Medical University International Medical Center)
(4)

March 17 (Fri) 17:00-18:30

Room15(Hotel Kanazawa, 4F, Emerald AB)

Chairperson: Kikuya Uno(Sapporo Heart Center / Heart Rhythm Center)
Satoru Sakagami(Clinical Research Department, Kanazawa Medical Center)
Speaker: Yoshihide Takahashi(Disaster Medical Center)
Toshiya Ohtsuka(Department of Cardiovascular Surgery, Tokyo Metropolitan Tama Medical Center)
Satoru Sakagami(Clinical Research Department, Kanazawa Medical Center)
Kikuya Uno(Sapporo Heart Center / Heart Rhythm Center)
Seiji Takatsuki(Keio University School of Medicine)
(5)Stop DAPT after PCI: How to Get Correct Answer
(※Partly in English)

March 18 (Sat) 8:30-10:00

Room15(Hotel Kanazawa, 4F, Emerald AB)

Chairperson: Takeshi Kimura(Kyoto University Hospital Cardiovascular Medicine)
Shinsuke Nanto(Nishinomiya Municipal Central Hospital)
Keynote Lecture: Thomas F. Lüscher(University of Zurich, Switzerland)
Speaker: Kenji Sakata(Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine)
Masato Nakamura(Toho University, Ohashi Medical Center)
Masahiro Natsuaki(Division of Cardiology, Saiseikai Fukuoka General Hospital)
Junya Ako(Cardiovascular Medicine, Kitasato University)
Shichiro Abe(Department of Cardiovascular Medicine, Dokkyo Medical University Heart Center)
(6)

March 18 (Sat) 17:20-18:50

Room11(Kanazawa Miyako Hotel, 7F, Hoh-Oh)

Chairperson: Yutaka Otsuji(Second Department of Internal Medicine, University of Occupational and Environmental Health)
Hirokuni Arai(Department of Cardiovascular Surgery, Tokyo Mecdical and Dental University)
Speaker: Kenji Iino(Department of Thoracic, Cardiovascular and General Surgery, Kanazawa University)
Masaaki Takeuchi(Department of Laboratory and Transfusion Medicine, University of Occupational and Environmental Health, School of Medicine)
Ken-ichi Hiasa(Cardiovascular Medicine, Kyushu University)
Kenji Minakata(Temple University School of Medicine, USA)
(7)
(※Partly in English)

March 18 (Sat) 17:20-18:50

Room15(Hotel Kanazawa, 4F, Emerald AB)

Chairperson: Yoshio Kobayashi(Department of Cardiovascular Medicine, Chiba University)
Nobuhiro Tanaka(Tokyo Medical University Hachioji Medical Center)
Keynote Lecture: Giulio Guagliumi(Ospedale Papa Giovanni XXIII, Italy)
Speaker: Hitoshi Matsuo(Department of Cardiovascular Medicine, Gifu Heart Center)
Kazuhiko Nishigaki(Department of Cardiology and Respirology, Gifu University Graduate School of Medicine)
Takashi Kubo(Department of Cardiovascular Medicine, Wakayama Medical University)
Junko Honye(Kikuna Memorial Hospital)
(8)

March 19 (Sun) 8:30-10:00

Room15(Hotel Kanazawa, 4F, Emerald AB)

Chairperson: Hiroyuki Daida(Department of Cardiology, Juntendo University Graduate School of Medicine)
Hiromi Rakugi(Department of Geriatric and General Medicine, Osaka University)
Speaker: Masa-aki Kawashiri(Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine)
Hidenori Arai(National Center for Geriatrics and Gerontology)
Satoshi Hoshide(Division of Cardiovascular Medicine, Jichi Medical University School of Medicine)
Koichi Yamamoto(Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine)
Junichi Oyama(Department of Circulation Regulation, Saga University)
Hiroshi Iwata(Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine)

Meet the Expert

(1)

March 17 (Fri) 8:50-10:20

Room13(Hotel Kanazawa, 2F, Diamond AB)

Chairperson: Shunji Sano(University of Clifornia San Francisco, USA)
Chisato Izumi(Department of Cardiology, Tenri Hospital)
Speaker: Satoshi Yasukochi(Heart Center Nagano Children's Hospital)
Naoki Yoshimura(Department of Cardiothoracic Surgery, University of Toyama)
Takeshi Arita(Heart Center, Kyushu University Hospital)
Hiroyuki Irie(Cardiovascular Surgery, Chikamori Hospital)
Mitsushige Murata(Department of Laboratory Medicine, Keio University School of Medicine)
Hiroki Yamaguchi(Showa University Koto Toyosu Hospital)
(2)New Aspects of Familial Hypercholesterolemia: from all Japan Points of View
(※Partly in English)

March 18 (Sat) 8:30-9:30

Room5(Hotel Nikko Kanazawa, 3F, Kujaku BC)

Chairperson: Shizuya Yamashita(Rinku General Medical Center)
Keynote Lecture: Latha Palaniappan(Stanford University School of Medicine, USA)
Speaker: Masa-aki Kawashiri(Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine)
Mariko Shiba(Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute)
(3)The Physical Examination is Alive & Well: Low-Tech, High-Yield Cardiac Diagnostics

March 18 (Sat) 9:30-10:30

Room5(Hotel Nikko Kanazawa, 3F, Kujaku BC)

Chairperson: Akira Yamashina(Department of Cardiology, Tokyo Medical University)
Speaker: Mark H. Swartz(Clinical Competence Center of New York, USA)
(4)

March 18 (Sat) 11:10-12:40

Room11(Kanazawa Miyako Hotel, 7F, Hoh-Oh)

Chairperson: Seiji Takashima(Department of Medical Biochemistry, Osaka University)
Toshihiro Tanaka(Bioresource Research Center, Tokyo Medical and Dental University)
Speaker: Hiroyuki Morita(Department of Cardiovascular Medicine, The University of Tokyo)
Seiko Ohno(Center for Epidemiologic Research in Asia, Shiga University of Medical Science)
Masayuki Yoshida(Tokyo Medical and Dental University)
Yoshimitsu Fukushima(Department of Medical Genetics, Shinshu University School of Medicine)
(5)

March 18 (Sat) 14:30-16:00

Room9(Kanazawa Miyako Hotel, B2F, Seminar Hall)

Chairperson: Koichiro Kinugawa(Second Department of Internal Medicine, University of Toyama)
Masafumi Kitakaze(Department of Clinical Medicine and Development, National Cerebral and Cardiovascular Center)
Speaker: Shuji Joho(Second Department of Internal Medicine, University of Toyama)
Hiroshi Asanuma(Department of Internal Medicine, Meiji University of Integrative Medicine)
Hiroshi Akazawa(Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo)
Yasuhiro Maejima(Department of Cardiovascular Medicine, Tokyo Medical and Dental University)
Osamu Tsukamoto(Department of Medical Biochemistry, Osaka University Graduate School of Medicine)
(6)Anticoagulation up to Date: RCT to the Real World
(※Partly in English)

March 18 (Sat) 17:50-18:50

Room5(Hotel Nikko Kanazawa, 3F, Kujaku BC)

Chairperson: Hideo Mitamura(Tachikawa Hospital)
Speaker: Peter A. Noseworthy(Mayo Clinic, USA)
Yukihiro Koretsune(Osaka National Hospital)
Masaharu Akao(National Hospital Organization Kyoto Medical Center)
(7)Clinical Significance of PCI for CTO Lesion
(※Partly in English)

March 19 (Sun) 8:30-10:00

Room5(Hotel Nikko Kanazawa, 3F, Kujaku BC)

Chairperson: Yuji Ikari(Department of Cardiology, Tokai University)
Kazushige Kadota(Department of Cardiology, Kurashiki Central Hospital)
Speaker: Toshiya Muramatsu(Cardiovascular Intervention and Therapeutics Center/Tokyo General Hospital)
Yoshihiro Morino(Iwate Medical University)
Hiroyuki Tanaka(Kurashiki Central Hospital)
Shuichiro Takanashi(Sakakibara Heart Institute)
Shun Kohsaka(Keio University School of Medicine)
(8)

March 19 (Sun) 11:10-12:40

Room14(Hotel Kanazawa, 2F, Diamond C)

Chairperson: Hirofumi Takemura(Department of Thoracic, Cardiovascular and General Surgery, Kanazawa University)
Kenji Okada(Division of Cardiovascular Surgery, Shinshu University School of Medicine)
Speaker: Masaaki Yamagishi(Department of Pediatric Cardiovascular Surgery, Children's Medical Center, Kyoto Prefectural University of Medicine)
Shigeyuki Ozaki(Toho University Ohashi Medical Center)
Tatsuhiko Komiya(Department of Cardiovascular Surgery, Heart Disease Center, Kurashiki Central Hospital)
Junjiro Kobayashi(Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center)
Toshiya Ohtsuka(Department of Cardiovascular Surgery, Tokyo Metropolitan Tama Medical Center )
Toru Kuratani(Minimally Invasive Cardiovascular Medicine, Osaka University Graduate School of Medicine)
(9)

March 19 (Sun) 11:10-12:40

Room15(Hotel Kanazawa, 4F, Emerald AB)

Chairperson: Hiroshi Kimura(Second Department of Internal Medicine, Nara Medical University)
Norifumi Nakanishi(Department of Cardiology, Minamiosaka Hospital)
Speaker: Yuichi Tamura(Pulmonary Hypertension Center, IUHW Mita Hospital)
Hiromi Matsubara(Department of Cardiology, Okayama Medical Center)
Masataka Kuwana(Department of Allergy and Rheumatology, Nippon Medical School, Graduate School of Medicine)
Hiroshi Kimura(Second Department of Internal Medicine, Nara Medical University)
Takeshi Ogo(Division of Pulmonary Circulation, National Cerebral and Cardiovascular Center)
Hitoshi Ogino(Department of Cardiovascular Surgery, Tokyo Medical University)
(10)

March 19 (Sun) 14:00-15:30

Room5(Hotel Nikko Kanazawa, 3F, Kujaku BC)

Chairperson: Naoki Sato(Cardiology and Intensive Care Unit, Nippon Medical School Musashi-Kosugi Hospital)
Mitsuaki Isobe(Department of Cardiovascular Medicine, Tokyo Medical and Dental University)
Speaker: Chiemi Taru(Department of Nursing Graduate School of Health Sciences, Kobe University)
Satoshi Miyake(Tokyo Medical and Dental University, Cancer Center)
Shogo Oishi(Department of Cardiology, Himeji Cardiovascular Center)
Dai Yumino(Yumino Heart Clinic)
Eisuke Matsushima(Section of Liaison Psychiatry and Palliative Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University)
Yasuki Kihara(Department of Cardiovascular Medicine, Hirosima University Graduate School of Biomedical & Health Sciences)
(11)

March 19 (Sun) 16:40-18:10

Room14(Hotel Kanazawa, 2F, Diamond C)

Chairperson: Shigeru Saito(Shonan Kamakura General Hospital)
Tetsuro Miyata(Sanno Hospital and Sanno Medical Center)
Speaker: Masahiko Fujihara(Cardiology, Kishiwada Tokushukai Hospital)
Nobuyoshi Azuma(Department of Vascular Surgery, Asahikawa Medical University)
Osamu Iida(Kansai Rosai Hospital)
Toshifumi Kudo(Division of Vascular Surgery, Tokyo Medical and Dental University)
Yoshimitsu Soga(Department of Cardiology, Kokura Memorial Hospital)

Morning Lecture

(1)

March 18 (Sat) 7:40-8:20

Room3(ANA Crowne Plaza Kanazawa, 3F, Ohtori)

Chairperson: Nobuyuki Ohte(Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences)
Speaker: Yoshihiro Seo(Cardiovascular Division, University of Tsukuba)
(2)

March 18 (Sat) 7:40-8:20

Room5(Hotel Nikko Kanazawa, 3F, Kujaku BC)

Chairperson: Yoshihisa Nakagawa(Department of Cardiology, Tenri Hospital)
Speaker: Masayuki Takamura(Department of Cardiology, Kanazawa University Hospital)
(3)

March 18 (Sat) 7:40-8:20

Room6(Hotel Nikko Kanazawa, 3F, Kujaku A)

Chairperson: Tesuo Minamino(Department of Cardiorenal and Cerebrovascular Medicine, Kagawa University)
Speaker: Yoshimichi Sai(Kanazawa University Hospital Pharmacy)
(4)

March 18 (Sat) 7:40-8:20

Room7(Hotel Nikko Kanazawa, 3F, La Grande Lumiere)

Chairperson: Minoru Yoshiyama(Department of Cardiovascular Medicine, Osaka City University Graduate School of Medicine)
Speaker: Yoshihiko Seino(Nippon Medical School Chiba Hokusoh Hospital, Cardiovascular Center)
(5)

March 18 (Sat) 7:40-8:20

Room9(Kanazawa Miyako Hotel, B2F, Seminar Hall)

Chairperson: Yoshihiro Fukumoto(Division of Cardiovascular Medicine, Kurume University School of Medicine)
Speaker: Noriaki Emoto(Clinical Pharmacy, Kobe Pharmaceutical University)
(6)

March 18 (Sat) 7:40-8:20

Room10(Kanazawa Miyako Hotel, 5F, Kaga)

Chairperson: Kyoko Soejima(Department of Cardiology, Kyorin University School of Medicine)
Speaker: Yukio Sekiguchi(Cardiovascular Division, University of Tsukuba)
(7)

March 18 (Sat) 7:40-8:20

Room11(Kanazawa Miyako Hotel, 7F, Hoh-Oh)

Chairperson: Takashi Kurita(Division of Cardiovascular Center, Kindai University)
Speaker: Toshiyuki Ishikawa(Department of Cardiology, Yokohama City University Hospital)
(8)

March 18 (Sat) 7:40-8:20

Room12(Kanazawa Miyako Hotel, 7F, Hishoh)

Chairperson: Takaaki Koshiji(Department of Cardiovascular Surgery, University of Fukui Hospital)
Speaker: Masahiko Zuka(Department of Forensic Medicine and Pathology, Kanazawa University)
(9)

March 18 (Sat) 7:40-8:20

Room13(Hotel Kanazawa, 2F, Diamond AB)

Chairperson: Hiroshi Furusho(Department of Cardiology, Kanazawa University Hospital)
Speaker: Masahiko Goya(Tokyo Medical and Dental University, Heart Rhythm Center)
(10)

March 18 (Sat) 7:40-8:20

Room14(Hotel Kanazawa, 2F, Diamond C)

Chairperson: Toshiaki Akita(Department of Cardiovascular Surgery, Kanazawa Medical University)
Speaker: Osamu Seguchi(Department of Transplantation, National Cerebral and Cardiorascular Center)
(11)

March 18 (Sat) 7:40-8:20

Room15(Hotel Kanazawa, 4F, Emerald AB)

Chairperson: Ken Kozuma(Division of Cardiology, Teikyo University Hospital)
Speaker: Satoru Sumitsuji(Department of Cardiology for International Education and Research, Osaka University)
(12)

March 18 (Sat) 7:40-8:20

Room16(Hotel Kanazawa, 5F, Party Room)

Chairperson: Tetsuya Amano(Departemnt of Cardiology, Aichi Medical University)
Speaker: Osamu Iida(Kansai Rosai Hospital)
(13)

March 18 (Sat) 7:40-8:20

Room17(Kanazawa Forus, 7F, Cinema 1)

Chairperson: Kazufumi Tsuchihashi(Division of Health Care Administration and Management, Sapporo Medical University)
Speaker: Yoshihiro Akashi(Division of Cardiology, St. Marianna University School of Medicine)
(14)

March 18 (Sat) 7:40-8:20

Room18(Kanazawa Forus, 7F, Cinema 2)

Chairperson: Kazuaki Tanabe(Fourth Department of Internal Medicine, Shimane University Faculty of Medicine)
Speaker: Hirotsugu Yamada(Department of Cardiovascular Medicine, Tokushima University Hospital)
(15)

March 19 (Sun) 7:40-8:20

Room3(ANA Crowne Plaza Kanazawa, 3F, Ohtori)

Chairperson: Shiro Iwanaga(Department of Cardiology, International Medical Center, Saitama Medical University)
Speaker: Masahiro Terashima(Cardiovascular Imaging Clinic Iidabashi)
(16)

March 19 (Sun) 7:40-8:20

Room5(Hotel Nikko Kanazawa, 3F, Kujaku BC)

Chairperson: Kazuo Kimura(Division of Cardiology, Yokohama City University Medical Center)
Speaker: Fuminobu Yoshimachi(Department of Cardiology, Tokai University School of Medicine)
(17)

March 19 (Sun) 7:40-8:20

Room6(Hotel Nikko Kanazawa, 3F, Kujaku A)

Chairperson: Shiro Uemura(Division of Cardiology, Kawasaki Medical School)
Speaker: Hitoshi Matsuo(Department of Cardiovascular Medicine, Gifu Heart Center)
(18)

March 19 (Sun) 7:40-8:20

Room7(Hotel Nikko Kanazawa, 3F, La Grande Lumiere)

Chairperson: Hatsue Ueda(Department of Pathology・ Baiobank, National Cerebral and Cardiovascular Center)
Speaker: Jun Koyama(Division of Cardiovascular Medicine, Shinshu University School of Medicine)
(19)

March 19 (Sun) 7:40-8:20

Room9(Kanazawa Miyako Hotel, B2F, Seminar Hall)

Chairperson: Kiyotaka Kugiyama(Internal Medicine II, University of Yamanashi)
Speaker: Satoaki Matoba(Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine)
(20)

March 19 (Sun) 7:40-8:20

Room10(Kanazawa Miyako Hotel, 5F, Kaga)

Chairperson: Takashi Yoneda(Program Management Office for Paradigms-Establishing Centers for Fostering Medical Researchers of the Future, Kanazawa University)
Speaker: Michihiro Yoshimura(Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine)
(21)

March 19 (Sun) 7:40-8:20

Room11(Kanazawa Miyako Hotel, 7F, Hoh-Oh)

Chairperson: Tsuyoshi Yoshimuta(Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine)
Speaker: Takeshi Ogo(Department of Advanced Medicine for Pulmonary Hypertension, National Cerebral and Cardiovascular Center)
(22)

March 19 (Sun) 7:40-8:20

Room12(Kanazawa Miyako Hotel, 7F, Hishoh)

Chairperson: Kouji Kajinami(Department of Cardiology, Kanazawa Medical University)
Speaker: Taku Iwami(Kyoto University Health Services)
(23)

March 19 (Sun) 7:40-8:20

Room13(Hotel Kanazawa, 2F, Diamond AB)

Chairperson: Mitsuru Ohishi(Department of Cardiovascular Medicine and Hypertension, Kagoshima University)
Speaker: Naoyuki Hasebe(Division of Cardiology, Nephrology, Pulmonology and Neurology, Asahikawa Medical University)
(24)Live from Washington DC – Late breaking from ACC
-DEFINE FLAIR and iFR-SWEDEHEART results

March 19 (Sun) 7:40-8:20

Room14(Hotel Kanazawa, 2F, Diamond C)

Chairperson: Akasaka Takashi(Wakayama Medical University)
Commentator: Yasutsugu Shiono(Imperial College London, UK)
Speaker: Justin Davies(Imperial College London, UK)
Matthias Gotberg(Lund University, Sweden)
(25)

March 19 (Sun) 7:40-8:20

Room15(Hotel Kanazawa, 4F, Emerald AB)

Chairperson: Kazuo Usuda(Toyama Prefectural Central Hospital)
Speaker: Youichi Kobayashi(Division of Cardiology, Showa University School of Medicine)
(26)

March 19 (Sun) 7:40-8:20

Room16(Hotel Kanazawa, 5F, Party Room)

Chairperson: Teruo Inoue(Department of Cardiovascular Medicine, Dokkyo Medical University)
Speaker: Kengo Tanabe(Division of Cardiology, Mitsui Memorial Hospital)
(27)

March 19 (Sun) 7:40-8:20

Room17(Kanazawa Forus, 7F, Cinema 1)

Chairperson: Naoki Nishida(Department of Legal Medicine, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama)
Speaker: Hayato Tada(Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine)
(28)

March 19 (Sun) 7:40-8:20

Room18(Kanazawa Forus, 7F, Cinema 2)

Chairperson: Yasuhiko Sakata(Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine)
Speaker: Kyoko Shibata(Innovative Clinical Research Center, Kanazawa University)
(29)

March 19 (Sun) 7:40-8:20

Room19(Kanazawa Forus, 7F, Cinema3)

Chairperson: Kazuo Kitamura(Department of Internal Medicine, Circulatory and Body Fluid Regulation, University of Miyazaki)
Speaker: Fumio Terasaki(Osaka Medical College, Medical Education Center)

Japan Heart Foundation Satoh Memorial Award Lecture

March 18 (Sat) 17:00-17:50

Room5(Hotel Nikko Kanazawa, 3F, Kujaku BC)